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Bone tissue engineering – where we are – the problems – the future
Bone has an amazing self-healing capacity and is one of the very few tissues in the
adult body that can heal itself without leaving scar tissue. One of the reasons why bone heals
well by itself (i.e. compared to articular cartilage) is its high level of vascularization.
Nevertheless, there are certain injuries where the normal healing capacity of bone is not
sufficient, like in large fracture gaps, non-unions or after tumor resection. A promising way to
heal these kinds of defects is by using tissue-engineered grafts. In bone tissue engineering,
the tissue defects or gaps are filled with constructs (grafts) that will be integrated into the
surrounding bone matrix and will eventually be replaced by newly formed bone through the
process of bone remodeling. Vascularization of the bone graft is essential, as already proven
by Cutting et al. in 1983 when he showed that vascularized autologous bone grafts were
superior to unvascularized grafts [1]. In fact, according to a review by Brandi, the importance
of the bone vascular system was already recognized by Albrecht von Haller in 1763 (though
not in conjunction with bone repair), when he stated that “the origin of bone is the artery
carrying the blood and in it the mineral element” [2]. Later, Trueta et al. showed that bone
vascularization is not only important for calcium homeostasis, but also plays a pivotal role
during bone tissue regeneration, mostly by supplying the damaged tissue with oxygen,
nutrients, growth factors and precursor cells [3, 4]. Insufficient vascularization is one of the
main problems encountered when dealing with critical-size full-thickness bone defects. The
present methods to heal these kinds of large defects combine long-term (external or internal)
fixation of the fracture with implantation of an autologous or allogenic bone graft. Since
allografts bring up immunological as well as ethical problems, autologous bone grafting is to
date the golden standard in orthopedic, oral- and plastic surgery. But despite the obvious
advantages of autografts, like its capacity for osteoconduction as well as -induction and
restricted immune reaction, there are also significant drawbacks, like its limited availability
(largely depending on the amount and shape of the autograft), as well as the induction of a
secondary defect at the donor site, followed by possible infection and morbidity at the donor
site [5, 6]. Therefore alloplastic grafts are becoming more and more interesting as an
alternative to autologous bone grafts. The obvious advantages are safety, virtually unlimited
supply and optimal adaptation to a specific situation.
Common components of an alloplastic graft include a scaffold, cells and biological factors.
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The scaffold
The scaffold principally provides the structural basis of a graft. But the demands on a
scaffold that could replace autologous grafts go much further than that. An ideal scaffold
should be biocompatible, biodegradable, porous, permeable to incoming cells, chemicals and
blood vessels, as well as supportive, inert, non-immunogenic, and of course it should be
easily available. Tissue engineered scaffolds should act as temporary matrices. Eventually,
blood vessels will invade the scaffold, new tissue will be formed and the scaffold will slowly
be resorbed by osteoclasts. The new tissue will be continuously remodeled and will
ultimately be reorganized into normal, healthy tissue [7, 8]. Commonly used scaffolds are
divided into natural scaffolds and synthetic (alloplastic) scaffolds. Natural scaffolds (i.e.
based on collagen or hyaluronic acid) are biodegradable, biocompatible and do not result in
harmful degradation products. However, some of them also have serious drawbacks like
limited cell adhesion, possible immunogenic response, inhibition of endothelial proliferation
(hyaluronic acid, HA) [9], structural weakness (fibrin glue) [10] or sub-optimal release of
incorporated growth factors (alginate, agarose) [11, 12]. Examples of ways to overcome
some of these problems at least partially include linkage of RGD-sequences to HA [13] or
heparin addition to alginate, agarose and fibrin glue [10, 14]. Synthetic scaffolds that have
been used in tissue engineering include ceramics (i.e. ß-tricalcium phosphates,
hydroxyapatites), polymers (i.e. polyurethanes PU, poly-L-lactic acids PLA, poly-D,L-lactic
acids PGLA, poly-glycolic acids PGA) and combinations. Problems with these kinds of
scaffolds include insufficient biodegradability (hydroxyapatite), hydrophobicity (PLA) [15],
excessive leakage (PLGA) [16] or potential toxicity of degradation products [15].
Polyurethane scaffolds
Polyurethanes (PU) are polymers containing a characteristic –NH-CO-O- linkage in
the chain. PU consists of flexible soft- and stiff hard-segments. Stable PU have been used
successfully in many medical devices, including many kinds of prostheses, tubings, catheters
and blood bags [17]. Recently, efforts have been made to design non-toxic biodegradable
PU to be used in tissue engineering by introducing labile units (non-aromatic compounds)
into the stable PU chains [18]. The more elastic material properties of polyurethanes allow a
mostly frictionless integration into the host tissue. The controllable degradation rate and
hydrophilic/hydrophobic ratio allows for optimal adaptation to the situation [19]. More
hydrophilic PU can be used as adhesion barriers, while more hydrophobic PU attract proteins
and support the attachment and growth of cells. Those PU can be used as biodegradable
scaffolds for bone tissue engineering. A recent study using polymers in the regeneration of
bi-cortical defects of the iliac crest in sheep have shown promising results [20].
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The cells
The main task of cells in tissue engineering is to produce a cell distribution and matrix
composition similar to the healthy in vivo situation. Implantation of an empty osteoconductive
scaffold will attract cells into the scaffold that eventually will form new bone tissue. This
approach works quite well for smaller defects (up to 3cm), and can be drastically accelerated
by seeding suitable cells into the scaffold before implantation [21-29]. In bone tissue
engineering, one obvious possibility would be to preseed scaffolds with mature autologous
culture-expanded osteoblasts. However, harvesting a piece of bone induces a severe
secondary defect at the donor site. Furthermore, there are different types of bone (cortical,
cancellous) containing different cell populations, which are at different maturation stages. A
more promising strategy is the use of mesenchymal stem cells (MSC) which can be easily
isolated from bone marrow aspirates using a much less invasive harvesting procedure. In
addition, the use of mesenchymal stem cells would allow the recapitulation of natural bone
formation and repair. Isolated MSC from bone marrow aspirates could be seeded directly into
the scaffold or, if needed, be expanded in vitro before being seeded into the scaffold.
Alternatively, one could induce a defined mature phenotype by stimulation of MSC with
suitable differentiation factors in vitro, before seeding them into the scaffold.
However, the limited long-term viability of these cells after implantation of the graft is a
limiting factor. The cells have to survive in an inhospitable environment until neo-
vascularization takes place, which will enable oxygen and nutrient supply to reach them. This
is the biggest problem of a large defect (>3cm). Therefore, accelerated vascularization of
critical-size bone grafts would be of great clinical value. One approach to improve neo-
vascularization could be to optimize the properties of the scaffold (i.e. chemical composition,
linker proteins or sequences, pore size, pore linkage). Another approach could be to seed
the scaffolds with an optimized cell-factor mixture prior to implantation, to promote vascular
formation within the graft.
Mesenchymal stem cells (MSC) in vitro
Stem cells are defined through their self-renewability (their division-capacity) and their
capacity to generate specialized cells. There are various types of stem cells, differing in the
time-point of their appearance during the development of an organism and in their versatility.
Pluripotent stem cells can give rise to all adult cell types. One example is embryonic stem
cells (ES), which derive from very early embryos (inner layer of the blastocyst). These cells
theoretically proliferate indefinitely in culture while retaining the potential to differentiate into
virtually any cell type [30]. Stem cells collected from older embryos or even adult tissue are
more restricted. They have limited proliferation capacity and generally differentiate within
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their tissue of origin (i.e. within the mesenchymal or hematopoietic system). Recent studies
have proposed trans-differentiation between different cell types of different germ layers, but
this topic is very controversial and still highly under discussion [31, 32]. Due to the current
legal and moral discussions about the usage of ES in clinical and therapeutic applications,
adult stem cells are, at this time, the precursor cell pool of choice.
In the bone marrow, hematopoiesis is supported by the stromal system [33, 34], which
consists of multipotent precursors for many mesenchymal cell types (called mesenchymal
stem cells, MSC) as well as reticular endothelial cells and macrophages [35-39]. In in vitro
experiments, marrow-derived cells were able to support and maintain hematopoietic cells
when used as a feeder layer, which underlines the hematopoiesis-supporting task of the
stromal component of bone marrow [33, 40]. The bone marrow stromal system has been
shown to be highly regenerative after high doses of irradiation, chemotherapy or marrow
ablation in young patients (<4yrs), although in older patients, the same treatments will result
in serious damage [41]. This is one of the reasons why it is still under discussion whether the
adult stromal system contains true stem cells, or just a very heterogeneous mixture of
lineage-specific undifferentiated precursor cells. MSC are recruited to their tissue of origin
through the blood circulation, where they differentiate into a specific mature cell type under
the influence of the local microenvironment. An extensive transdifferentiation potential
between mature cell types within the mesenchymal cell family has recently been shown,
replacing the earlier belief that mesenchymal stem cells were restricted to a certain cell type
once they have reached their tissue of fate and are differentiated into a mature cell [42].
In 1970, Friedenstein was the first to isolate MSC by plating bone marrow-derived cells on
plastic, where the adherent fraction would form fibroblastic colonies (each colony originating
from one single stromal cell clone). These colonies were termed colony-forming unit
fibroblastic (CFU-F) [43]. Under the right culture conditions, they could give rise to
osteoblasts (CFU-O) and chondrocytes (CFU-C) [44-49] as well as to other mesenchymal
cell types including adipocytes [50] and tenocytes [51]. Aubin and others have shown that
single CFU-F can be very heterogeneous in size, morphology and differentiation potential
[37, 52, 53]. Studies looking at the three main mesenchymal lineages (osteogenic,
chondrogenic, adipogenic) have shown that the MSC population consisted of tripotential
(30%), bipotential (osteo-chondrogenic (60-80%), but no osteo-adipogenic or chondro-
adipogenic) and unipotential (osteogenic, no chondrogenic or adipogenic) precursors.
Interestingly, their chondrogenic and adipogenic but not osteogenic potential was lost over
culture time [50, 54]. This suggests that the adult stromal system consists of a very
heterogeneous precursor population containing just a small fraction of possibly pluripotent
stem cells, but a large fraction of pre-committed mesenchymal precursors of varying
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differentiation potential, and that the default cell lineage of the these precursors is the
osteoblastic one. Another fact supporting the hypothesis that MSC contain no or very little
real stem cells is that MSC can be expanded almost indefinitely (>260 population doublings)
when transformed with the telomerase gene [55], but they reach senescence after 35-40
population doublings when untransformed [56]. Also, their progenitor properties are gradually
lost with extensive culture expansion [57]. Addition of b-FGF to MSC cultures has been
shown to enhance their proliferative potential while keeping the cells in a more
undifferentiated state. This was demonstrated by an increased Stro-1 expression (a marker
prominently expressed by CFU-F), a decreased number of ALP-positive clones, a longer
preservation of the typical fibroblastic phenotype and the potential to differentiate into
osteoblasts, chondrocytes or adipocytes even after extensive expansion [58-60].
Today, bone marrow aspirate is considered to be the most enriched and easily accessible
source of mesenchymal precursors from which MSC can quickly be isolated, expanded and
differentiated into various lines in vitro. Other possible sources of mesenchymal precursors
include trabecular bone [61], blood [62], periosteum [63, 64], dermis [65], muscle [66, 67], fat
[68] and the synovial membrane [69]. These alternative sources of MSC are, however, less
used due to lower MSC concentrations than that found in the bone marrow, as well as to
more complex and less standardized harvesting, expansion and differentiation methods.
The terms mesenchymal stem cells (MSC) and bone marrow stromal cells (BMSC) are
generally used quite interchangeably even though BMSC and MSC are not exactly the same.
Both cell pools are believed to derive from the same ancestor, but MSC appear more
undifferentiated and show a more homogenous and fibroblastic cell phenotype, while BMSC
are less homogenous and show fibroblastic as well as stromal (hematopoiesis-supporting)
characteristics and might include endothelial cells and macrophages [40, 70, 71].
Blood vessels – endothelial cells
Blood vessels are part of the circulatory system, transporting blood to and from
almost any part of the body. This is achieved by branching of the macrovasculature (arteries,
veins) into microvasculature (arterioles, venules) and finally into capillaries. The capillaries
serve to redistribute blood and its nutrients whilst lowering the pressure head, allowing blood
to diffuse into the tissue and thereby allowing better nutrient distribution. The blood vessels
found in bone are mainly microvascular vessels and capillaries. Capillaries have an inner
lining of endothelial cells, which provides a surface that prevents blood cell attachment and
thrombus formation. This endothelial layer is surrounded by pericytes that share a common
basal lamina with the endothelial cells [72]. The basal lamina is approximately 40-50 nm thick
and serves as a separation and isolation layer between the connective tissue and the
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endothelium. It is composed of the lumina lucida (adjacent to the endothelial cells and made
of the proteoglycan laminin and type IV collagen) and the lumina densa (made of type VII
collagen). In addition to pericytes, microvascular vessels are surrounded by smooth muscle
cells and fibroblasts. Pericytes and smooth muscle cells are responsible for expansion and
contraction of the vessels. Pericytes have also been suggested to serve as osteoblastic
precursors [73, 74].
Blood vessel formation can take place by three distinct processes: vasculogenesis,
angiogenesis and arteriogenesis [75]. Vasculogenesis is the de novo vessel-forming process
that takes place during early embryonic development. Endothelial cells differentiate from their
precursors, the angioblasts, and proliferate within a previously avascular tissue to form a
primitive tubular capillary network. Vasculogenesis is followed by angiogenesis, during which
this initial vascular network is remodeled into more complex networks through vessel
enlargement, sprouting, and bridging. Another (non-sprouting) angiogenic mechanism is the
intussusceptive microvascular growth (IMG), during which existing vessel lumens are divided
by formation of interstitial tissue folds. Arteriogenesis is the process of structural enlargement
and remodeling of preexisting small arterioles into larger collateral vessels. There are many
biological factors known to be involved in the molecular mechanisms of all these processes.
Some of these factors have been known for a long time and are not specific for blood vessel
formation (FGF, PDGF, TGF-) [75-78], while others are believed to be more specific and
critical. Those include members of the vascular endothelial growth factor family (VEGF) and
of the angiopoietin family [79-81]. During bone remodeling and repair, new microvascular
vessels invade the injured site mainly through the process of angiogenesis.
Bone cell – endothelial cell interactions
Sufficient vascularization is very important for normal bone turnover and repair [82].
Endothelial cells are located inside the blood vessels forming a single layer, adhering tightly
to the basement membrane of the vessel’s wall, providing a non-thrombogenic surface to
which platelets and other blood cells fail to adhere. Furthermore, they mediate the passage
of nutrients and other solutes across the blood-tissue barrier. In bone development, the
appearance of osteoblasts coincides with blood vessel invasion [83]. This suggests that
endothelial cells could be a major source of modulators of bone development, turnover and
repair. This hypothesis is also supported by the fact that the replacement of the cartilage
during endochondral bone formation is accompanied by the capillary invasion from the
mineralized cartilage, following the release of angiogenic factors from the hypertrophic
chondrocytes [84, 85]. Guenther et al. were the first to report in vitro interactions between
endothelial cells and bone cells by showing that bovine aortic endothelial cells produce a
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mitogen for rat calvarial cells [86]. Several EC-produced factors that affect bone cells and
vice versa have been discovered and several studies covering the topic of endothelial cell –
osteoblastic cell interactions have been performed over the last few years [87-96].
Nevertheless, the outcomes of these studies were very diverse and experiments were often
performed only over a rather short time period (for a more detailed discussion see chapter II),
leaving many unknowns about the long-term effect of such interactions, especially in a 3D
environment.
The biological factors
At a fraction site, one of the first elements to appear are platelets. This is followed by
platelet activation, aggregation and clotting. Chemotactic factors are released attracting
various types of cells. Neutrophilic granulocytes are usually the first cells to enter the wound
site, followed by monocytic phagocytes (which differentiate into macrophages at the site of
inflammation), then fibroblasts, osteoblasts, vascular endothelial cells and various precursor
cells [97]. The factors that are produced by platelets during the very early phase of bone
repair include FGF, PDGF, IGF, TGF-, TGF-ß and VEGF [98-101]. Local administration of
exogenous TGF-1, TGF-2, PDGF-BB or b-FGF at fracture sites results in improved bone
formation and/or chondrogenesis [102-109]. It is understood that the formation of new tissue
is very dependent on the local dose and timing of these growth factors and cytokines.
VEGF and angiopoietin
VEGF is the best-characterized factor active during vascularization and angiogenesis.
It induces hyperpermeability of vessels [110], degradation of the surrounding extracellular
matrix and allows endothelial (precursor-) cell-recruitment, migration and reorganization into
sprouting tubules (this complicated process involves also FGF, PDGF and TGF-). Adult
blood vessels are stabilized through angiopoietin-1 (Ang1) by binding to (and therefore
activating) its receptor Tie2. During angiogenic remodeling, for example as a response to
hypoxia [111] or tissue rupture, angiopoietin-2 (Ang2) is up-regulated and binds Tie2
receptor, thereby preventing Ang1 from binding. The action of Ang2 depends largely on
VEGF. Ang2 mediated vessel destabilization can lead to endothelial cell death and vessel
regression in the absence of VEGF, or to vessel sprouting in the presence of VEGF [112].
Matrix metalloproteinases also play a pivotal role in the matrix degradation during vessel
sprouting [113]. The new vessel tubules are then remodeled and covered by pericytes,
fibroblasts and potentially smooth muscle cells, which form a new extracellular matrix of
basal lamina in response to TGF-. The vessels then enter a quiescent state. Ephrins, even
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though initially characterized in the nervous system, have recently been shown to also play a
role during angiogenic remodeling. They are most probably involved in the establishment of
the venous versus the arterial system [114].
From:
Ramsauer M, D’Amore P, Getting Tie(2)d up in angiogenesis, J Clin Invest, 110:1615-1617 (2002)
The factor generally (and therefore also in this thesis) referred to as VEGF is correctly
named VEGF-A and is a member of a family also containing VEGF-B, -C, -D and placenta
growth factor (PLGF). VEGF is by far the most studied and understood member of this
family. VEGF-B seems to be involved in coronary vascularization and growth, but its role is
not really understood yet [115]. VEGF-C and –D are believed to regulate lymphatic
angiogenesis [116]. Through alternate mRNA splicing, four different isoforms of VEGF are
produced: VEGF121, VEGF165, VEGF189 and VEGF 206 with 121, 165, 189 and 206 amino
acids after signal sequence cleavage [117]. VEGF165 is the predominant isoform [118]. The
165, 189 and 206 splice variants have heparin-binding domains, which help to anchor them
in the extracellular matrix (ECM). These domains are also responsible for the higher
mitogenic activity of VEGF165, VEGF189 and VEGF 206 compared to the non heparin-binding
isoform VEGF121 [119]. VEGF121 is freely diffusible, while VEGF189 and VEGF206 are almost
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completely sequestered in the extracellular matrix. VEGF165 has intermediate characteristics:
A fraction of it is freely diffusible; the other fraction is bound to the cell surface and the
extracellular matrix [120]. These observations suggest that VEGF165 has an optimal
combination of bioavailability and mitogenic potential and indeed, it is the main active VEGF
during angiogenesis [117].
VEGF can bind to several different cell surface tyrosine kinase receptors. VEGF binds to
VEGFR1 (formerly known as Flt-1) and VEGFR2 (Flk-1/KDR). VEGF-B and PLGF bind only
to VEGFR-1. VEGF-C and –D bind to VEGFR-2 and -3 (Flt-4). In addition there are a number
of accessory receptors such as the neuropilins, which are believed to be mainly involved in
modulating the binding to the main VEGF receptors [121]. VEGFR2 seems to mediate the
growth and permeability actions of VEGF whereas VEGFR1 is suggested to have a negative
role (decoy receptor), but its exact function is still under debate [122]. Interestingly, VEGFR2
binds VEGF with lower affinity than VEGFR1 [123-125]. There is also a soluble splice variant
of VEGFR1 (sFlt-1), which has been shown to compete with the binding of VEGF to VEGFR1
[126]. Mice lacking VEGFR2 fail to develop a vasculature and show low numbers of
endothelial cells, while mice lacking VEGFR1 show excess formation of endothelial cells with
abnormal tube formation [127, 128]. Another VEGF-receptor, VEGFR3, seems to be critical
for the development of the lymphatic vessel system [129].
VEGF works in close relation with other factors, especially with angiopoietins. Angiopoietins
are ligands for a family of receptor tyrosine kinases called Tie. The two most important
angiopoietin family members are Ang1 and Ang2, both binding to Tie2. Knockout
experiments have shown that mouse embryos lacking Ang1 or Tie2 developed a rather
normal primary vasculature (unlike VEGF knockouts), but this vasculature failed to undergo
further remodeling. Over-expression of Ang1 in skin resulted in a modest increase in vessel
number, but in a significant increase in vessel size as well as in resistance to leak [130]. On
the other hand, VEGF over-expression primarily increased the number of vessels, but these
were leaky [131]. Over-expression of both factors resulted in an unprecedented
hypervascularity resulting from increased vessel number and size. Interestingly, the vessels
were still resistant to leak (induced by VEGF or inflammatory agents) [130]. Ang2 plays a
very confusing role by being able to act as an agonist or antagonist to Tie2. The suggested
role of Ang2 is a signal for destabilization of the vessel during the initiation of angiogenesis. It
has been suggested that autocrine Ang2 has a different effect than paracrine Ang2 and that
the effect of this factor depends largely on the presence of other factors including VEGF or
Ang1 [132-134].
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Modified from:
Yancopoulos et al., Vascular-specific growth factors and blood vessel formation, Nature 407:243 (2000)
The importance of VEGF during coupling of bone formation with cartilage resorption was
demonstrated by Gerber et al., who showed that blocking VEGF results in suppression of
blood vessel invasion, connected with impaired trabecular bone formation and expansion of
the hypertrophic chondrocyte zone [135]. More recent in vivo data indicates that VEGF is not
only important for bone vascularization, but also plays a role in the differentiation of
hypertrophic chondrocytes, osteoblasts and osteoclasts [136, 137]. VEGF is secreted by
many cell types including hypertrophic chondrocytes, osteoblasts and osteoblast-like cells
and its expression is influenced by many cytokines, growth factors and hormones (i.e. IGF-1,
PGE1, PGE2, Vit.D3, PTH, TGF-, BMP-2, -4, -6) [93, 138-141]. Several groups have
reported a direct effect of VEGF on osteoblastic cells (stimulation of migration, proliferation
and differentiation) [93, 142, 143], however opposite findings suggest that further studies are
necessary to resolve this controversy [91, 141]. Since angiopoietins have been discovered a
few years later than VEGF, their exact role in angiogenesis and bone formation is less
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understood. Ang1 and 2 have been detected in similar regions within bone as VEGF
(cartilage-bone interface, remodeling sites). They are also expressed by various cell types
including osteoblasts, osteoclasts and marrow space cells [144]. Angiopoietins do not seem
to have a direct mitogenic effect on endothelial cells, even though the Tie2 receptor becomes
activated.
Platelet-rich plasma (PRP)
Platelet-rich plasma (PRP) is autologous plasma with a platelet concentration around
five times higher than that found in blood. It also contains an increased number of growth
factors in their natural ratios upon platelet activation. Known growth factors released by
activated PRP include PDGF-AA, PDGF-AB, PDGF-BB, TGF-b1, TGF-b2, VEGF and EGF
[145]. The obvious advantage of PRP over the use of recombinant growth factors is the fact
that it can be produced from the patient’s blood intraoperatively. Recombinant human growth
factors are usually synthesized by Chinese hamster ovarian cells transfected with human
genes, and are delivered at non-physiological doses. In addition, while PRP forms a gel that
is a prerequisite for growth factor delivery, recombinant growth factors are delivered using a
synthetic carrier or a carrier processed from animal proteins. The PRP gel, in addition to
containing the platelet released growth factors, will also be able to entrap cells, thus making
PRP an easy and inexpensive source of autologous matrix and biological factors.
Platelet activation cascade: Platelets adhere to ruptured vessel walls by binding to von Willebrand factor and
are activated upon exposure to collagen. The release of agonists like thrombin or ADP (generated at the sites of
vascular trauma) results in a conformational shape change of the platelets, followed by degranulation, and the
release of many growth factors and cytokines. The platelets then bind to circulating fibrinogen through their GP
IIb-IIIa receptors to form large platelet-fibrin aggregates.
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The key molecular players in osteogenesis
In a classic study, Urist described ectopic bone induction by intramuscular
implantation of demineralized bone matrix (DBM) in rabbits and rats. This was a key
discovery, which stimulated the search for a bone-inducing substance in the bone matrix.
Subsequent investigations demonstrated that low-molecular weight proteins could be
extracted from demineralized bone matrix [146]. These proteins showed more osteogenic
activity than DBM, and were therefore termed bone morphogenetic proteins (BMPs) [147-
150]. Today, several signaling molecules in addition to BMPs are known to play a role in
controlling skeletal development, including other members of the transforming growth factor
family (TGF-), FGF, secreted factors of the Wnt-family and members of the hedgehog
family [151-153]. The following paragraphs will describe the proteins and transcription factors
involved in osteoblastic differentiation that will be investigated and evaluated in this thesis:
BMP: Around 20 genes coding for BMPs have been identified so far, and several
recombinant BMPs have been shown to have a unique activity, which is to induce ectopic
bone formation [147, 154-156]. Osteoblasts secrete BMP into their matrix during bone
formation. BMPs (except for BMP-1 which is a peptidase) are members of the TGF-
superfamily, known to regulate cell proliferation, differentiation and death in various tissues
[154, 157-160]. Many studies confirmed the hypothesis that BMPs are involved in the
regulation of osteoblastic and chondrocytic differentiation by identifying skeletal abnormalities
in individuals with mutations in BMP genes [161-167]. The mechanism off ectopic bone
formation by recombinant BMPs was investigated using osteoblastic differentiation in in vitro
experiments. Several BMPs enhance typical osteoblastic markers like ALP, type I collagen,
osteocalcin and MMP-13 [168]. In addition, BMPs stimulate the formation of mineralized
bone-like nodules in vitro [169].
Runx2: Runx2 (Cbfa1) is the -subunit of a heterodimeric transcription factor consisting of
Runx2 and the -subunit Cbf. Runx2 is a structural homologue of the runt-gene product in
Drosophila. It contains a conserved region (the Runt domain), which is required for
dimerization with the -subunit as well as for binding to OSE2 (osteoblast-specific cis-acting
element), first discovered in the mouse osteocalcin gene 2 promotor (OG2) [170, 171]. There
are two more -subunits, Runx1 and Runx3, but none of them seems to be involved in
osteoblastic differentiation and bone formation [172, 173]. In Runx2-null mice, the
osteoblastic differentiation is completely blocked [174]. Cbf-null mice show much less
deficiency in bone formation than Runx2-null mice, indicating that Runx2 can control bone
formation to a limited degree in the absence of Cbf [175, 176]. Runx2 is not osteoblast-
specific; it also plays a role in the differentiation of hypertrophic chondrocytes [174, 177].
Over-expression of Runx2 in chondrocytes results in an accelerated endochondral
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ossification [178]. Regulation of osteoblastic differentiation by members of the TGF-
superfamily (i.e. TGF-1 and BMP-2) is believed to act through interactions of Smads with
Runx2 [179].
In summary, Runx2 is required for early osteoblastic differentiation as well as hypertrophic
chondrocyte differentiation.
Osterix: Osterix (Osx, SP7) is a zinc-finger containing transcription factor highly specific for
osteoblasts [180]. Osx-null mice show normal cartilage development but completely lack
bone formation: A dense mesenchyme emerges in the zone of hypertrophic chondrocytes
accompanied by blood vessels and osteoclasts. However, the mesenchymal cells are
blocked in their differentiation. Arrested differentiation in these cells was shown by
significantly reduced type I collagen expression, as well as undetectable osteoblastic
markers including osteonectin, osteopontin, bone sialoprotein and osteocalcin. Interestingly,
Runx2 expression levels were normal. This observation, together with the finding that Runx2-
null mice showed no Osx transcripts suggests, that Osx and Runx2 are part of the same
osteoblastic differentiation pathway and that Osx acts downstream of Runx2. This is also
supported by studies comparing Runx2-null and Osx-null mice. In Runx2-null mutants,
hypertrophic chondrocyte differentiation is inhibited and there is no invasion of the
hypertrophic zone by blood vessels and osteoclasts. In Osx-null mutants though,
hypertrophic chondrocyte differentiation is not impaired and the hypertrophic zone is invaded
by blood vessels and osteoclasts, but osteoblastic differentiation does not occur.
Interestingly, Runx2-null mutants show a significant decrease in VEGF expression by
chondrocytes, which could explain the lack of blood vessel invasion into the hypertrophic
cartilage zone of these mutants.
Based on the studies described above, a model for osteoblastic differentiation was proposed
[181]: Mesenchymal progenitor cells differentiate first into preosteoblasts under the control of
Runx2/Cbf. These preosteoblasts are bipotent, thus have the ability to differentiate into
either chondrocytes or osteoblasts upon the right stimuli. However, when Osx is turned on,
these bipotent cells are driven towards the osteoblastic pathway, while if Sox-9 is turned on
they will differentiate into the chondrogenic lineage. Interestingly, studies comparing the
effect of Sox9 inactivation before and after chondrogenic mesenchymal condensations have
indicated that expression of Sox9 was required for the establishing of bipotential osteo-
chondro-progenitor cells [182]. Once the chondrogenic mesenchymal condensation was
completed, Sox9 was no longer needed for the osteoblast lineage, and Osx was suggested
to be the negative regulator of Sox9. So Osx seems to be the regulator that segregates the
osteoblastic from the chondrogenic differentiation pathway.
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Dlx5: Dlx5 (distal-less homeobox 5) is a bone inducing transcription factor that is expressed
in differentiating osteoblasts [183]. Dlx5-null mice show severe craniofacial abnormalities
with delayed ossification and of the cranium and abnormal osteogenesis [184]. Interestingly,
it has been shown that BMP-2 induction of Osterix expression is mediated by Dlx5 (and not
by Runx2) [185].
Osteoblastic markers
Progression of osteoblastic differentiation is currently best described by the temporal
expression of bone matrix proteins [186]. The relevant markers investigated in this thesis are
quickly introduced below:
Collagen type I (COL1): Type I collagen is the major organic component of the bone matrix
and is found in mineralized and non-mineralized areas. Interestingly, the collagen in
mineralized tissue aligns differently from that in non-mineralized tissue to leave space for the
apatite crystals [187, 188]. Type I collagen is secreted by osteoblasts prior to matrix
mineralization [189] and is one of the early markers during osteoblastic differentiation [190].
Osteocalcin (OC): OC (earlier name bone GLA-protein) is the major non-collagenous
protein in bone (10-20%). It’s synthesized only by mature osteoblasts, therefore represents a
late marker of osteogenesis [52, 190, 191]. OC is generally found in mineralized tissue and is
a very useful marker to follow the osteoblastic differentiation in the rat model, although in
human it is less useful [192] (see also our findings in chapter II).
Osteopontin (OP): OP is a phosphorylated glycoprotein expressed very early in bone cell
differentiation and again later following mineralization. OP is highly abundant in bone, but
can also be found in hypertrophic chondrocytes, kidney and in very small amounts in the
brain and lungs. OP binds very firmly to hydroxyapatite and probably plays a role in the
attachment and spreading of bone cells (it contains an RGD sequence) [52, 190, 193].
Osteonectin (ON): ON is a calcium and hydroxyapatite-binding glycoprotein that is also
found in the lung, ovaries and other tissues. However, it is highly abundant in bone and a
common marker of osteoblastogenesis [190, 191, 194].
Bone Sialoprotein II (BSP): BSP is a phosphorylated bone specific glycoprotein mainly
found in mineralized tissue. It appears late during osteogenesis [52, 190, 191, 195, 196].
Collagenase 3 (MMP-13): The matrix metalloproteinases (MMPs) are a family of
proteinases that are able to degrade extracellular matrix components (in particular collagens)
[197]. MMP-13 was discovered in 1994 in connection with breast carcinomas [198] and was
later found to be a major player during endochondral bone formation by efficiently degrading
type II collagen, but also aggrecan and type I and IV collagens. MMP-13 is under the control
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of the transcription factor Runx2 and is expressed as a late differentiation marker in
osteoblasts [199].
ALP: Alkaline Phosphatase is a cell-surface ectoenzyme that hydrolyses monophosphate
esters. Its precise physiological role is not completely clear yet. One important function is to
cleave phosphate groups from OP, ON, OC and BSP to make them available for the process
of matrix mineralization. ALP activity rises in early stages of culture, peaks before the onset
of mineralization and decreases after mineralization (not expressed in osteocytes) [200, 201].
Matrix mineralization: Matrix mineralization is most often measured by 45Ca2+ -isotope
incorporation into the matrix and by Van Kossa staining [202]. Determination of calcium
incorporation is a very powerful tool to judge osteoblastic differentiation not only because it is
a very late event in osteogenesis but also because it measures the performance of an active
“bone-forming” process.
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Thesis aims
The overall goal of this PhD thesis was to define a construct to be used in bone tissue
engineering that has the potential to improve in vivo vessel formation within the construct.
Bone healing is always in very close association with vessel formation and ingrowth [3, 4,
203-208]. It has even been shown, that bone formation is blocked, if endothelial invasion is
inhibited [209]. We were therefore interested in the involvement of endothelial cells in bone
formation.
 Our first aim was to study the interactions of endothelial cells (EC) and
mesenchymal stem cells (MSC) to investigate the hypothesis that EC influence
MSC differentiation into an osteoblastic phenotype, and that this effect is
modulated by soluble factors and/or direct contact.
One of the first events in a fracture is the formation of a blood clot to prevent further bleeding.
The platelets in these clots then release factors and cytokines responsible for cell recruitment
and other initial events during early fracture repair (see section “The biological factors”).
Platelet-rich plasma (PRP) has been suggested to have the potential to improve bone
healing.
 Our second aim was to test the usability of PRP as a source of autologous
biological factors and if it could stimulate MSC differentiation into an osteoblastic
phenotype.
Bone defects of less than 3cm can usually be healed using autologous bone grafts.
However, the grey zone is defects between 3 and 8cm, which are still a major clinical
problem. Surgeons have tried to use scaffolds made of synthetic or natural materials that
promote the migration, proliferation and differentiation of bone cells. However, these
approaches have been shown to be only limited successful. Furthermore, the absence of an
appropriate blood vessel network in such large defects is an additional concern.
 Therefore, our third and last aim was to develop a construct based on the
outcome of aims 1 and 2, and to evaluate its potential to form vessel-like
structures in vitro, as well as its capacity to induce MSC differentiation into
osteoblasts.
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Chapter II
Human endothelial cells inhibit human MSC
differentiation into mature osteoblasts in vitro by
interfering with Osterix expression
Meury TR, Alini M.
Our first experiments were based on the initial hypothesis of this PhD:
MSC differentiation into osteoblasts is modulated by interactions with EC
To investigate this hypothesis, we decided to use 2D co-culture systems for simplicity
and reproducibility reasons. Two non-direct contact co-culture systems were chosen
(trans-wells and conditioned medium). Direct contact co-cultures were left out due to
the difficulty of culturing EC and osteoblastic cells in the same culture medium for
long term without addition of growth factors or cytokines that enhance EC survival,
and due to the difficulty in separating contributions of each cell type when analyzing
markers.
This chapter is a manuscript submitted for publication to J Cell Biochem.
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Introduction
Mesenchymal stem cells (MSC) derive from the adherent, mononucleated
fraction of bone marrow [1]. It has been shown, that this cell pool contains precursors
for several mesenchymal tissue cells including osteoblasts, fibroblasts, chondrocytes,
adipocytes and myoblasts [2-4]. Bone marrow stroma is actually suggested to be the
main source for osteoblastic precursors [3]. Recruitment, proliferation and
differentiation of MSC into mature osteoblasts are regulated by many factors
including cytokines, systemic hormones, growth factors and other regulators [5].
These factors are released by the osteoblastic cells themselves, but also by cells that
are part of the tightly connected vascular system, such as endothelial cells [6-8] or
pericytes [9]. Endothelial precursors can be isolated from bone marrow, as well as
from peripheral blood [10;11]. During embryonic development, the major vascular
network is formed by vasculogenesis, mediated mainly by factors belonging to the
vascular endothelial growth factor (VEGF) family [12]. VEGFs bind to several
receptors including Flt-1 (VEGFR-1) and KDR (VEGFR–2 or Flk-1) that have been
identified on many cells types, including endothelial and osteoblastic cells [13-15].
VEGFs promote vascular endothelial cell proliferation and induce vascular leak and
permeability, which allows the initial network to be remodeled by angiogenic
sprouting [16;17], a process in which the immature and poorly functional vascular
network is remodeled into a complex network of mature and stable blood vessels
[18]. It is widely accepted that there must be communication between endothelial
cells and osteoblastic cells in order to regulate blood vessel formation, osteoblast
differentiation and bone turnover, processes that are all very tightly connected [19-
24]. In vivo and in vitro experiments suggest a paracrine communication between
endothelial cells and osteoblastic cells using gap junctions to mediate the angiogenic
process required for bone formation and repair [25]. VEGF is believed to play an
important role in these processes [6;9;26-29]. It was shown, in a mouse model, that
angiogenesis, bone formation and callus mineralization in femoral fractures do not
occur, if VEGF activity is inhibited [8]. In vitro studies have shown that VEGF has a
stimulatory effect on osteoblastic differentiation [30], however it does not seem to
have a direct effect on osteoblastic precursor cell proliferation [7;31]. VEGF is
definitely not the only factor involved in these communication processes. There are
several other factors that are expressed and secreted during bone healing and that
can affect osteoblastic cells or endothelial cells, including PDGFs, TGFs, FGFs,
angiopoietins and endothelins [32-35].
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In vitro studies about the influence of endothelial cells on osteoblastic differentiation
have shown a remarkable variety of results [6;7;9]. These differing results are partly
due to the different cell (lines) and culture conditions used as well as due to different
donor age and biopsy site. In addition, we hypothesize that the differentiation state of
endothelial cells, following stimulation with different factors, could play an important
role on how they influence MSC differentiation. In the present study, we have grown
endothelial cells with or without VEGF stimulation and investigated their effect on
MSC differentiation towards the expression of an osteogenic phenotype.
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Materials and Methods
Origins of human cells
Bone marrow aspirates were taken from patients undergoing routine
orthopedic surgery involving iliac crest exposure, after informed consent. Bone
marrow aspirates (20mL) were harvested into CPDA-containing Sarstedt monovettes
using a biopsy needle that was pushed through the cortical bone. Aspirates were
processed within 12-24 hours after harvesting.
Isolation and expansion of human MSC
Bone marrow aspirates were homogenized by pushing them a few times
through a syringe. The aspirate was then diluted 1:4 with IMDM (Gibco 42200-022)
containing 5% (v/v) FBS (Gibco 10270-106) and centrifuged at 200g for 5min at room
temperature (RT). The top layer (approx. 1cm) containing mostly fat tissue was
removed. Per 1mL of undiluted sample, 2.6mL of Ficoll (Histopaque-1077, Sigma
#1077-1) were pipetted into a 50mL Falcon tube and the aspirate was added
carefully on top of the Ficoll. After centrifugation at 800g for 20min at RT, the
mononucleated cells were collected at the interphase using a syringe. To 1mL of
collected interphase solution, 5mL of IMDM/5%FBS were added, the tube was gently
mixed and centrifuged at 400g for 15min at RT. The pellet was resuspended in the
same amount of IMDM/5%FBS, centrifuged again and resuspended in
IMDM/5%FBS. Cell number was determined using Methylene Blue in a
hemocytometer. The cells were seeded at densities of 8-10 *106 mononucleated cells
per 150cm2 T-flask in IMDM containing 10% FBS, nonessential aminoacids (Gibco
11140-035) and PenStrep (100U/mL, Gibco 15140-122). After 5 days, the
monolayers were washed with Tyrode’s balanced salt solution (TBSS) to remove
non-adherent cells, and fresh medium containing 5ng/mL b-FGF (R&D 233-FB) was
added as previously reported [36-38]. Medium was changed every 2-3 days and
cells were subcultured 1:3 at subconfluence. The adherent cells after one subculture
were termed mesenchymal stem cells (MSC). Only cells between passages 2-4
(approx. 12-18 populations doublings) were subsequently used [39].
Expansion of HUVEC
Primary Human Umbilical Vein Endothelial Cells (HUVEC) were obtained
from Cascade Biologics (cat# C-003-5C). The cells were expanded in IMDM
containing 10%FBS, nonessential aminoacids, PenStrep, 20ug/mL ECGS (Sigma E-
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2759) and 90ug/mL heparin (Sigma H-3149). Only cells between passages 2-4 were
subsequently used.
Stimulation of HUVEC with VEGF
HUVEC were expanded in IMDM containing 10% FBS, nonessential
aminoacids, 20ug/mL ECGS, 90ug/mL heparin and PenStrep. At about 75% of
confluency, 25ng/mL VEGF (Sigma V-7259) were added and the cells were
stimulated for 3 days [8]. The HUVEC monolayers were then either used to produce
HUVEC-conditioned medium (see Conditioned medium (VEGF stimulated or non-
stimulated) on MSC cultures)) or were trypsinized and used for indirect contact co-
cultures.
MSC cultures
MSC were seeded in 24-well plates (Falcon BD 353504) at densities of
10’000 to 30’000 cells/well in 1mL of medium and were left to attach for 2-3 hours.
Culture medium for the MSC culture systems contained IMDM, 10% FBS,
nonessential aminoacids, 0.1mM ascorbic acid-2-phosphate (Sigma A-8960) and
10mM  -glycerophosphate (Sigma G-6251) with 10nM dexamethasone (osteogenic
medium) or without dexamethasone (non-osteogenic medium). Dexamethasone was
purchased at Sigma (D-2915). Media were changed twice a week.
Conditioned medium (VEGF stimulated or non-stimulated) on MSC cultures
HUVEC-conditioned medium was produced by washing the VEGF stimulated
(see section “Stimulation of HUVEC with VEGF”) or non-stimulated HUVEC
monolayers 2x with phosphate buffered saline (PBS) and then culturing them for 24h
in IMDM containing 10% FBS and PenStrep. After 24h, the medium (defined as
VEGF-stimulated or non-stimulated HUVEC-conditioned medium) was removed,
filtered (0.22µm), and stored at -20°C until used. This HUVEC-conditioned medium
was added in a 1:10 mixture to MSC monolayers cultured in osteogenic or non-
osteogenic medium in 24-well plates. Chondrocyte-conditioned medium (Chondro-
CM) using primary bovine chondrocytes and fibroblast-conditioned medium (Fibro-
CM) using the human hTERT-BJ1 fibroblast cell line were also similarly prepared and
applied accordingly.
Indirect contact cultures of MSC and HUVEC (VEGF stimulated or non-stimulated)
To MSC monolayers, VEGF stimulated (see section “Stimulation of HUVEC
with VEGF”) or non-stimulated HUVEC were added in cell culture inserts (0.4µm
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pore size, Falcon BD 353495) at a density of 10’000 cells/insert. Fresh HUVEC were
added once a week to the system to provide a fresh supply of endothelial cell
secreted factors. These experiments were also performed in osteogenic or non-
osteogenic medium.
Recovery Experiment
MSC were grown in osteogenic (or non-osteogenic) medium supplemented
1:10 with non-stimulated HUVEC-conditioned medium, as described above. At
different time points, medium supplementation with HUVEC-conditioned medium
(non-stimulated) was stopped, and the MSC were grown in osteogenic (or non-
osteogenic) medium. On day 27, the osteogenic differentiation stage of MSC was
evaluated by determining matrix mineralization and OSX gene expression.
Inhibition experiment
MSC were grown in osteogenic medium (non-osteogenic medium as negative
control). At different time points, the medium was switched to osteogenic medium
containing non-stimulated HUVEC-conditioned medium (1:10). After 28 days, the
osteogenic differentiation was evaluated by determining ALP activity and OSX gene
expression.
DNA quantification
The protocol used for DNA quantification was based on the method described
by Labarca et al. [40], which involves the binding of Hoechst 33258 to the minor
groove of the DNA double helix resulting in a measurable enhancement in
fluorescence. MSC were digested by adding 0.5mL proteinase K (0.5mg/mL
proteinase K in phosphate buffer containing 3.36mg/mL disodium-EDTA) solution
directly to the wells and incubating the plates at 56°C for 1h. Thereafter, the digested
cells were transferred to Eppendorf tubes to avoid evaporation and were further
digested overnight at 56°C. After appropriate dilution with Dulbecco’s phosphate
buffered saline (DPBS) containing 0.1% (v/v) H33258 (from 1mg/mL stock,
Polysciences Inc, 09460), the samples were measured using a PE HTS 7000 Bio
Assay Reader at 360nm excitation and 465nm emission wavelength.
Quantification of matrix mineralization using 45Ca2+ isotope
1.25µCi/mL of 45Ca2+ isotope (Amersham CES3) were added to each well and
the plates were incubated at 37°C for 6h [41]. The medium was removed and the
monolayers were washed 3x with IMDM to remove unincorporated 45Ca2+. Then
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0.5mL of 70% formic acid were added to each well and the plates were incubated at
65°C for 1h. The formic acid solution was then transferred to 3.5mL of scintillation
liquid (OptiPhase HiSafe’3 by Perkin Elmer) and the amount of radioactivity was
measured using a Wallac 1414 WinSpectral liquid scintillation counter.
Quantification of alkaline phosphatase activity
The medium was completely removed and the monolayers were washed
once with PBS. The cell layers were extracted by addition of 500µL of 0.1%Triton-X
in 10mM Tris-HCl (pH 7.4) and incubation at 4°C on a gyratory shaker for 2h (See
Sigma Technical Bulletin Procedure No.104). ALP activity was measured
colorimetrically by measuring the p-nitrophenol production during 15min incubation at
37°C with p-nitrophenyl phosphate as substrate (Sigma Kit No.104) on a Perkin
Elmer Bio Assay Reader HTS 7000.
Quantification of VEGF amounts in the culture supernatant
Culture medium was collected and VEGF (165,121)-protein content was
measured using a DuoSet ELISA Development System for human VEGF by R&D
Systems (DY293) on a Perkin Elmer Bio Assay Reader HTS 7000.
RNA Isolation and Reverse Transcription
Monolayers were extracted using 500µL of TRI-Reagent (MRC Inc. TR-118)
with 5ul/mL of Polyacryl-carrier (MRC Inc. PC-152) for 10min at RT and transferred
to Eppendorf tubes. 150mL of 1-Bromo-3-Choro-Propane were added, the tubes
vortexed for 15sec and then centrifuged at 12’000g for 15min at 4°C. The colorless
layer on the top was transferred into a new tube and 750µL of isopropanol were
added, then the tube was centrifuged at 12’000g for 10min at 4°C. Sample
supernatants were removed and pellets were washed in 1mL of 75% EtOH by
vortexing and centrifuging at 10’000g for 5min at 4°C. Pellets were air-dried and re-
suspended in 30µL of DEPC-treated water. After 15min at 60°C, tubes were
immediately transferred to ice. The total RNA amount and purity was assessed by
measuring the absorbance at 260nm and 280nm. Reverse transcription was
performed using 1µg of total RNA sample, which was mixed with 2µL of 10x TaqMan
RT Buffer (500mM KCl, 100mM Tris-HCl, pH 8.3), 4.4µL of 25mM magnesium
chloride, 4µL of dNTP mixture (2.5mM of each dNTP), 1µL of random hexamers
(50µM), 0.4µL of RNase inhibitor (20U/mL) and 0.5µL of MultiScribe Reverse
Transcriptase (50U/µL) (all from Applied Biosystems); DEPC-treated water was
added to bring the final reaction volume to 20µL. Reverse transcription was
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performed using a Thermal Cycler 9600 by Applied Biosystems. cDNA samples were
appropriately diluted with Tris-EDTA buffer before being used for real-time RT PCR.
Real-time RT PCR
Oligonucleotide primers and TaqMan probes were designed using the Primer
Express Oligo Design software (Ver. 1.5, Applied Biosystems). The nucleotide
sequences were obtained from the GenBank database and the probes were
designed to overlap an exon-exon junction in order to avoid amplification of genomic
DNA (Table I). Primers and probes for amplification of 18S ribosomal RNA, used as
endogenous control, were from Applied Biosystems. All other primers and labeled
TaqMan probes were from Microsynth (Balgach, CH). TaqMan probes were labeled
with the reporter dye molecule FAM (6-carboxyfluorescein) at the 5´end and with the
quencher dye TAMRA (6-carboxy-N, N, N´, N´-tetramethylrhodamine) at the 3´end.
The PCR reaction mixture contained TaqMan Universal PCR master mix without
AmpErase UNG (Applied Biosystems), 900nM primers (forward and reverse), 250nM
TaqMan probe, and 2l of cDNA sample for a total reaction volume of 25l. PCR
conditions were 95°C for 10min, followed by 42 cycles of amplification at 95°C for
15sec and 60°C for 1min using the GeneAmp 5700 Sequence Detection System
(Applied Biosystems, Foster City, CA). Relative quantification of mRNA targets was
performed according to the comparative CT method with 18S ribosomal RNA as
endogenous control (ABI PRISM 7700 Sequence Detector User Bulletin 2, PE
Applied Biosystems 1997).
Van Kossa staining
MSC monolayers were rinsed with TBSS. A silver nitrate solution (5%) was
added and the cells were exposed to strong light for 20min. After rinsing 3 times with
distilled water, the cells were incubated in fresh 5% sodium thiosulfate for 10min.
After rinsing 3 times with distilled water, 0.1% nuclear fast red solution was added
and the cells were incubated for 10min, before being washed again with distilled
water. Samples were left in distilled water and pictures were taken immediately.
Statistical analysis
The data are expressed as mean±SEM unless stated otherwise. Statistics
were performed using the non-parametric Mann-Whitney U-test, which compares the
medians of two independent distributions. P < 0.05 was considered statistically
significant.
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Table I. Primers and Probes for Real-Time RT-PCR
Target Gene Sequence (5’  3’)
Collagen I
Forw CCC TGG AAA GAA TGG AGA TGA T
Rev ACT GAA ACC TCT GTG TCC CTT CA
Probe CGG GCA ATC CTC GAG CAC CCT
Osteonectin
Forw ATC TTC CCT GTA CAC TGG CAG TTC
Rev CTC GGT GTG GGA GAG GTA CC
Probe CAG CTG GAC CAG CAC CCC ATT GAC
MMP-13
Forw CGG CCA CTC CTT AGG TCT TG
Rev TTT TGC CGG TGT AGG TGT AGA TAG
Probe CTC CAA GGA CCC TGG AGC ACT CAT GT
BMP-2
Forw AAC ACT GTG CGC AGC TTC C
Rev CTC CGG GTT GTT TTC CCA C
Probe CCA TGA AGA ATC TTT GGA AGA ACT ACC AGA AAC TG
Osteocalcin
Forw AAG AGA CCC AGG CGC TAC CT
Rev AAC TCG TCA CAG TCC GGA TTG
Probe ATG GCT GGG AGC CCC AGT CCC
Osteopontin
Forw CTC AGG CCA GTT GCA GCC
Rev CAA AAG CAA ATC ACT GCA ATT CTC
Probe AAA CGC CGA CCA AGG AAA ACT CAC TAC C
Runx2
Forw AGC AAG GTT CAA CGA TCT GAG AT
Rev TTT GTG AAG ACG GTT ATG GTC AA
Probe TGA AAC TCT TGC CTC GTC CAC TCC G
BSP II
Forw TGC CTT GAG CCT GCT TCC
Rev GCA AAA TTA AAG CAG TCT TCA TTT TG
Probe CTC CAG GAC TGC CAG AGG AAG CAA TCA
Osx, Sox 9, Collagen II and PPAR :
Primers and Probes: Assay-On-Demand by Applied Biosystems
(Assays: Hs00541729_m1, Hs00165814_m1, Hs00264051_m1,
Hs00234592_m1)
Probes were modified at the 5’ end with the FAM fluorescent dye (6-
carboxyfluorescein) and at the 3’ end with the TAMRA fluorescent dye (6-
carboxy-N,N,N’,N’-tetramethylrhodamine). Assay-On-Demand probes had a
non-fluorescent quencher at the 3’end.
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Results
Bone marrow aspirates from seven human donors (age range 44-66 years)
were obtained. Each experiment was done with cells from at least three different
donors. Due to the high variability in the osteogenic potential of MSC between
donors, some data are shown from one representative experiment, although, the
same trends were observed in all three experiments, and they are summarized in
Table II. The MSC used for the experiments were expanded using b-FGF to increase
the cell number while keeping them in a tripotential state capable of osteogenic,
chondrogenic and adipogenic differentiation [36-38].
Table II. Summary of the mean data observed in each single experiment
Col 1 gene expression day 24 rel to MSC in OM
Condition A B C
MSC in osteogenic medium (OM) 1.00 1.00 1.00
MSC in OM with HUVEC 0.59 0.59 0.73
MSC in OM with HUVEC (VEGF) 0.49 0.54 0.52
ON gene expression day 24 rel to day 1 and to MSC in OM
Condition A B C
MSC in osteogenic medium (OM) 1.00 1.00 1.00
MSC in OM with HUVEC 0.28 0.52 0.69
MSC in OM with HUVEC (VEGF) 0.25 0.20 0.65
BMP-2 gene expression day 24 rel to day 1 and to MSC in OM
Condition A B C
MSC in osteogenic medium (OM) 1.00 1.00 1.00
MSC in OM with HUVEC 0.24 0.17 0.78
MSC in OM with HUVEC (VEGF) 0.16 not detectable 0.69
MMP-13 gene expression day 24 rel to day 1 and to MSC in OM
Condition A B C
MSC in osteogenic medium (OM) 1.00 1.00 1.00
MSC in OM with HUVEC 0.55 0.01 0.99
MSC in OM with HUVEC (VEGF) 0.06 0.01 0.71
Indirect contact co-culture versus conditioned medium culture
Two different types of HUVEC-MSC culture systems were used; the first,
using a trans-well system, allowed indirect 2-way communication between the two
cells types; and the second, HUVEC-conditioned medium, allowed 1-way
communication from HUVEC to MSC but not vice versa. Since no significant
differences in the results could be observed between the two culture types, we will
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not distinguish anymore between them, and we will generally discuss our results as:
Effect of HUVEC on MSC differentiation.
Effect of HUVEC on MSC differentiation in non-osteogenic medium
In preliminary experiments, the effect of HUVEC on MSC differentiation when
cultured in non-osteogenic medium was investigated. HUVEC did not show any
effect on ALP activity or matrix mineralization of MSC compared to the control (no
HUVEC). This suggested that HUVEC were not able to replace the positive effect of
dexamethasone on MSC differentiation into osteoblasts in these in vitro culture
systems (data not shown).
Effect of HUVEC on MSC differentiation in osteogenic medium (OM)
As a positive control, MSC were cultured in osteogenic medium without
HUVEC. As expected, this led to an increase of several osteoblastic markers, such
as matrix mineralization and ALP activity (Figures 1-3).
Furthermore, we observed an elevated expression of typical early and late
osteoblastic marker genes including collagen 1 (COL1), osteonectin (ON), matrix
metalloproteinase 13 (MMP-13), and bone morphogenetic protein 2 (BMP-2), when
compared to MSC cultured in non-osteogenic medium (Figure 4a-d).
Figure 1: Representative graph of ALP activity of MSC: MSC grown in osteogenic medium (OM)
showed a clear increase in ALP activity compared to MSC in non-osteogenic medium. HUVEC
significantly (P < 0.005) reduced the increase in ALP activity of MSC. VEGF-stimulated HUVEC further
reduced ALP activity (P < 0.05). Statistical analyses were performed for day 24 (n=6).
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Figure 2:
45
Ca isotope incorporation of MSC at day 24 of culture (n=9): MSC grown in osteogenic
medium (OM) showed high matrix mineralization, while MSC in non-osteogenic medium did not.
Cultures of MSC and HUVEC showed a significant decrease in matrix mineralization when compared to
MSC grown alone. This inhibitory effect was enhanced, when HUVEC were previously stimulated with
VEGF.
Figure 3: Van Kossa staining of MSC grown in osteogenic medium (a) and MSC grown in osteogenic
medium supplemented with HUVEC-conditioned medium (b). Calcium deposition is clearly inhibited by
the presence of HUVEC.
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The addition of non-stimulated HUVEC to MSC cultures significantly decreased ALP
activity (Figure 1), matrix mineralisation (Figures 2 and 3) and mRNA levels of COL1,
ON, MMP-13 and BMP-2 (Figure 4). There was a slight increase in the DNA content
of MSC upon addition of non-stimulated HUVEC, but this increase was not significant
(data not shown).
Figures 4a-d: Representative graphs of mRNA levels of Collagen type I (a), Osteonectin (b), MMP-13
(c) and BMP-2 (d) measured by real-time RT-PCR: MSC cultured in osteogenic medium (OM) resulted
in an upregulation of osteoblastic marker genes compared to MSC in non-osteogenic medium. Cultures
with HUVEC decreased the expression of these marker genes significantly, an effect that was
enhanced, when HUVEC were previously stimulated with VEGF. Day 24 data from all three experiments
are summarized in Table II.
Osterix (OSX) was expressed at almost undetectable levels early in culture. After 24
days, MSC cultured in non-osteogenic medium still showed low OSX expression,
while MSC in osteogenic medium expressed OSX prominently. HUVEC significantly
decreased OSX gene expression of MSC, suggesting an inhibitory effect on MSC
differentiation (Figure 5).
Chapter II: HUVEC inhibit hMSC differentiation into mature osteoblasts in vitro by interfering with Osx…
46
Figure 5: Osterix (OSX) mRNA levels relative to MSC in OM at day 24 (n=4): At day 1, OSX mRNA
levels were almost undetectable in all cultures (data not shown). At day 24, MSC grown in non-
osteogenic medium showed low OSX expression, while MSC grown in osteogenic medium (OM)
showed elevated OSX expression. This expression was significantly down-regulated by HUVEC. Again,
VEGF-stimulated HUVEC showed a more pronounced inhibitory effect.
Interestingly, Sox-9 expression levels dropped with culture time and reached almost
undetectable levels in all cultures supplemented with osteogenic medium, including
those with HUVEC (Figure 6). When VEGF-stimulated HUVEC were added to MSC,
we observed an even more inhibitory effect on the measured markers than with non-
stimulated HUVEC (Figures 1-6).
Figure 6: mRNA levels of the chondrocytic marker Sox-9 at day 24 relative to day 1 (n=4): The
expression of Sox-9 dropped significantly after 24 days in all cultures, suggesting that none of these
culture conditions propagates a chondrocytic phenotype. However, MSC cultured in osteogenic medium
(OM) showed a more significant reduction of Sox-9 expression than MSC cultured in non-osteogenic
medium. Unstimulated HUVEC had no effect on the inhibition of Sox-9 expression by OM, but VEGF-
stimulated HUVEC significantly further decreased Sox-9 expression of MSC. Collagen 2 (COL2),
another chondrocytic marker, was almost undetectable in all cultures during the whole experiment (data
not shown).
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We have also evaluated osteopontin (OP), osteocalcin (OC), bone sialoprotein II
(BSP) and Runx2 gene expression. OP was highest at the very beginning of all
cultures, then dropped and rose again with time in culture. Interestingly, MSC
cultured in non-osteogenic medium showed higher OP expression than MSC in
osteogenic medium (data not shown). When MSC were cultured with HUVEC, OP
expression was further decreased. OC expression was constantly low in all culture
systems, and almost undetectable in osteogenic medium. Addition of HUVEC didn’t
show any effect on OC (data not shown). Bone sialoprotein II (BSP) gene expression
was decreased by HUVEC (data not shown). Runx2 expression was always higher in
cultures with osteogenic medium and slightly increased in all cultures over time.
HUVEC didn’t change this pattern (data not shown).
Recovery Experiment
In order to evaluate whether the observed inhibitory effect of HUVEC on MSC
differentiation was reversible, we cultured MSC in osteogenic medium with the
addition of non-stimulated HUVEC-conditioned medium (1:10) and replaced it at
different time points with only osteogenic medium. As expected, MSC that were
exposed to osteogenic medium containing non-stimulated HUVEC-conditioned
medium (1:10) during the whole experiment showed inhibition of 45Ca+2 incorporation.
Upon removal of non-stimulated HUVEC-conditioned medium, all these MSC
cultures showed matrix mineralization similar to the positive control (Figure 7).
Interestingly, MSC that were in contact with HUVEC-conditioned medium for a longer
period of time (17 and 24 days) incorporated more calcium into their matrix upon
HUVEC-conditioned medium removal, than MSC that were in contact with HUVEC-
conditioned medium for a shorter period of time (3 and 10 days) (Figure 7). OSX
gene expression was also analyzed and showed a similar picture (data not shown).
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Figure 7:
45
Ca incorporation of
MSC in osteogenic
medium (OM) at day 27
after removal of HUVEC
at different time points
(n=4): Calcium deposition
by MSC was inhibited by
HUVEC, but upon
removal of HUVEC, MSC
showed again significant
matrix mineralization.
Interestingly, it seemed
that the longer MSC were
cultured with HUVEC-
conditioned medium, the
higher was the amount of
45
Ca incorporated into
their extracellular matrix,
after removal of HUVEC-conditioned medium (a). OSX gene expression showed a similar response
upon removal of HUVEC-conditioned medium (data not shown).
Inhibition experiment
To investigate at which times HUVEC could interfere with the MSC
differentiation process, we cultured MSC in osteogenic medium and then replaced it
with osteogenic medium containing non-stimulated HUVEC-conditioned medium
(1:10) at different time points. The analysis of OSX gene expression showed, that
osteoblastic differentiation was suppressed shortly after the medium was switched to
medium containing non-stimulated HUVEC-conditioned medium (1:10). Even after 21
days of osteogenic stimulation, addition of non-stimulated HUVEC-conditioned
medium resulted in a 4-5x decrease in OSX expression at day 28 compared to MSC
in osteogenic medium (Figure 8b). ALP activity showed a similar pattern (Figure 8a).
Figure 8a/b: Representative graphs of ALP activity (a) and OSX gene expression (b) of MSC: At
different timepoints, the osteogenic medium (OM) was replaced by HUVEC-conditioned medium. The
differentiation process was suppressed by the addition of HUVEC-conditioned medium, as judged by
the inhibition of ALP activity (a) and suppression of OSX expression levels (b).
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Chondro-CM and Fibro-CM on MSC
To investigate, if the inhibitory effect described in the previous sections was
specific to HUVEC, we cultured MSC in osteogenic medium supplemented with
chondrocyte-conditioned medium as well as with fibroblast-conditioned medium. Both
Chondro-CM and Fibro-CM did not alter the calcium incorporation by MSC or the
expression of osterix, while HUVEC-CM, in accordance with the results described
above, was able to significantly down-regulate calcium incorporation as well as
osterix gene expression (Figures 9a/b).
Figures 9a/b:
45
Ca incorporation (a) and OSX gene expression (b) of MSC in osteogenic medium
supplemented with endothelial- (HUVEC-CM), chondrocyte- (Chondro-CM) or fibroblast-conditioned
medium (Fibro-CM).
45
Ca-incorporation was significantly down regulated by HUVEC-CM, while
Chondro-CM or Fibro-CM had no effect. Osterix gene expression showed the same pattern.
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VEGF protein levels in culture media
We have measured the VEGF protein levels at several time points in the
culture supernatant to investigate whether VEGF concentrations would be altered in
the co-cultures compared to MSC alone. The highest amount of VEGF was observed
in MSC cultured in non-osteogenic medium, while in osteogenic medium VEGF was
down regulated. HUVEC had no effect on VEGF protein levels measured in the
culture supernatant (data not shown).
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Discussion
In the present study, we have investigated the effect of HUVEC on MSC
differentiation towards the expression of an osteoblastic phenotype. The
differentiation of MSC by osteogenic medium was inhibited following exposure to
HUVEC. This was reflected by a significant decrease in matrix mineralization, ALP
activity and in reduced expression of specific osteoblastic genes, including MMP-13,
COL1, BMP-2 and ON. Interestingly, OC gene expression seems not to be an
appropriate differentiation marker in human cells, as previously reported [42].
HUVEC were co-cultured with MSC for up to 28 days in two different types of culture
systems: indirect contact and HUVEC-conditioned medium. The direct contact co-
culture system was not used due to the difficulty of identifying specific markers of
either HUVEC or MSC when cultured together, as well as to the lack of a suitable
culture medium that could support the growth of MSC and HUVEC together for more
than just a few days, without addition of growth factors (EGF, PDGF, VEGF,
bFGF…). Interestingly, the observed inhibitory effect of HUVEC on MSC
differentiation was seen in both co-culture systems, indicating that HUVEC secrete
one or several factors that can delay MSC differentiation. Furthermore, it appears
that this factor(s) acts by inhibiting OSX expression and therefore arresting MSC
differentiation at a pre-osteoblastic stage (Figure 10). It has been shown that Runx2
plays a role in the commitment-step to osteo-chondro progenitor cells whereas OSX
acts mainly on the terminal differentiation of osteoblasts and on distinguishing the
osteogenic pathway from the chondrogenic one [43]. This might explain why Runx2
is not affected by HUVEC. The suppression of OSX expression by HUVEC could
even be induced at later stages of MSC differentiation, just before mineralization of
the extracellular matrix would have started. In addition, the reversibility of the HUVEC
inhibitory effect on MSC differentiation was demonstrated by our recovery
experiment, which showed that upon removal of HUVEC-conditioned medium, MSC
could rapidly further differentiate towards the expression of an osteoblastic
phenotype. Interestingly, this last experiment also indicates that MSC exposed to
HUVEC for longer periods of time, seem to differentiate even faster towards an
osteoblastic phenotype upon removal of HUVEC, when compared to MSC that have
never been in contact with HUVEC (Figure 7).
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Figure 10: A simplified schematic representation of the different stages of the differentiation of MSC into
osteoblasts: We postulate, that HUVEC may have the ability to arrest osteoblastic differentiation in a
pre-osteoblastic stage by inhibiting OSX gene expression. The inhibitory effect of HUVEC does not
result in an increase of chondrocytic or adipocytic markers. In vivo, this could lead to an accumulation of
pre-osteoblasts at sites of bone turnover and repair.
It is also important to note that MSC exposed to HUVEC-CM showed no
COL2 expression (data not shown) and extremely low expression of Sox-9, two
typical markers of the chondrogenic phenotype (Figure 6). There was also no
increase in the expression of the adipocytic marker PPAR-gamma over time (data
not shown). These observations suggest that HUVEC-conditioned medium does not
drive MSC towards the expression of a chondrogenic or an adipogenic phenotype.
Together, our data from this in vitro system suggest that endothelial cells can
increase the osteogenic potential of osteoprecursor cells while keeping them in a pre-
osteoblast state (but at a later stage than the bipotential precursor stage for
chondrocytes and osteoblasts, since Runx2 expression is unchanged by HUVEC). In
addition, this effect is specific to HUVEC, since chondrocyte- as well as fibroblast-
conditioned medium did not show this inhibitory effect on MSC. This would correlate
with the in vivo potential of endothelial cells to recruit large numbers of osteogenic
precursor cells at sites of bone modeling or remodeling. Further studies are
necessary to verify this speculation.
Few studies have focused on the interactions of endothelial cells and osteoblastic
cells in the past years, and the outcomes of these studies were somewhat divergent.
While the positive influence of endothelial cells on osteoblastic cell proliferation has
been reported quite consistently, their influence on osteoblastic cell differentiation
seems rather controversial [6;7;9]. Wang et al. reported an increase in ALP activity in
human osteoblast-like cells when cultured in HUVEC-conditioned medium [6], while
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Jones et al. showed a decrease in ALP activity of MSC when cultured on EC feeder
layers [9]. Villars et al. showed a decrease in ALP activity in all non-direct contact co-
cultures, but an increase in ALP activity in direct contact co-cultures, but also a
decrease in osteocalcin synthesis in direct contact co-cultures [7]. Kaigler et al.
showed increased ALP activity as well as OC secretion only when MSC and EC were
co-cultured in direct contact [44]. Guillotin et al. showed that different kinds of primary
endothelial cells were able to induce ALP activity of osteoprogenitors when co-
cultured in direct contact for up to 6 days, while transformed endothelial cells lines
showed no effect [45]. Stahl et al. used EC and osteoblasts in an in vitro 3D
spheroidal co-culture model. They described spontaneous organization of
osteoblasts and endothelial cells into a core and a surface layer as well as changes
in the gene expression patterns of both cell types, including an increase in ALP
activity and down-regulation of VEGF after 48h, but did not distinguish between the
two cell types during analysis [46;47]. Furthermore, all the studies mentioned above
were carried out for a rather short period of time. Our preliminary studies showed no
effect of EC on MSC differentiation in non-osteogenic medium (in no-direct contact
co-cultures), which is in accordance with the above reports.
During the formation of a vascular network, endothelial progenitors originating from
hemangioblasts differentiate into mature endothelial cells, which then participate in
the processes of vasculogenesis and angiogenesis to form a mature vascular
network. Especially in bone, this capillary network is constantly remodeled, which
includes destabilization of vessels and sprouting of new branches, processes that are
believed to require a change in the differentiation/maturation state of the vessel-
covering endothelial cells. Therefore, this change in “maturation” of endothelial cells
might influence their effect on MSC differentiation. These vessel remodeling
processes are controlled by several factors, the most important one probably being
VEGF [48]. Indeed, as observed in the present study, stimulation of HUVEC by
VEGF further increases their inhibitory action on MSC differentiation. This inhibition
could not be reproduced by VEGF itself. In fact, we could not detect any VEGF
protein (results not shown) in the HUVEC-conditioned media (both VEGF-stimulated
and non-stimulated) added to the MSC, as previously also reported by Villars et al.
[7]. This conclusion is also supported by the observations that VEGF expression in
MSC is decreased by glucocorticoids both in vivo and in vitro; that VEGF protein was
detected in MSC cultures but its level did not show any changes upon addition of
HUVEC-conditioned medium or HUVEC in indirect contact; and that Stahl et al. even
measured a down-regulation of VEGF in their 3D direct contact co-culture model
[46;47]. Furthermore, MSC cultured in non-osteogenic media (no dexamethasone)
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showed higher levels of VEGF, again indicating that glucocorticoids suppress VEGF
expression.
In conclusion, we have shown that HUVEC specifically have an inhibitory
effect on dexamethasone-induced MSC differentiation in vitro. This effect is most
probably due to a yet unknown HUVEC secreted factor(s), which suppresses OSX
expression, therefore arresting MSC differentiation at a pre-osteoblastic stage.
Furthermore, prior stimulation of HUVEC with VEGF resulted in a further increased
inhibitory effect of HUVEC on MSC differentiation. A tempting speculation arising
from these data is that HUVEC might regulate the rate at which MSC differentiate
into osteoblasts, by initiating the recruitment of osteoprecursor cells at sites of bone
remodeling and by keeping them in a pre-osteoblastic stage. This would avoid
mineral deposition within vessels, but once these pre-osteoblastic cells extravasate
out of the vessel and continue their homing to the remodeling/repair site, they will
rapidly differentiate into mature osteoblasts and lay down new osteoid tissue.
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Chapter III
Effect of Ang1 and a combination of Ang1 and VEGF
on osteoblastic differentiation of MSC
Meury TR, Alini M
After the interesting results obtained following VEGF-stimulation of HUVEC (see
chapter II), we decided to investigate another factor involved in angiogenesis. While
VEGF is mainly responsible to induce vascular leak, angiopoietin-1 (Ang1) is
involved in the stabilization and maturation of blood vessels. We therefore decided to
investigate the effect of Ang1 stimulated HUVEC on MSC differentiation.
This chapter is not planned as a publication in the current form.
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Introduction
Vasculogenesis and angiogenesis are critical processes during bone
development, turnover and repair [1-5]. In vitro and in vivo studies have shown, that
endothelial cells interact closely with osteoblastic cells [6-13] (see also chapter II).
Angiopietin-1 (Ang1) is probably the best-described angiogenic factor next to
vascular endothelial growth factor (VEGF). VEGF is the most critical driver of
vascularization and is mainly responsible for induction of vascular permeability and
leak [14, 15]. Ang1 works in concert with VEGF [16, 17] but is restricted to later
stages of angiogenesis where it plays a main role during the maturation and
stabilization of blood vessels. This was illustrated by studies showing that mice
lacking Ang1 develop a rather normal primary vasculature (unlike mice lacking
VEGF), but the vasculature fails to undergo further remodeling and maturation [18].
Interestingly, recent studies have shown synergistic actions of VEGF and Ang1
during angiogenesis [19, 20], neovascularization [21, 22] and other in vivo assays
[23, 24].
In chapter II, we were able to show that VEGF had a significant effect on how human
umbilical vein endothelial cells (HUVEC) influence human mesenchymal stem cell
(MSC) differentiation. Unstimulated HUVEC were able to down-regulate
dexamethasone-induced osteogenic differentiation of MSC in vitro. This inhibitory
effect was significantly enhanced when HUVEC were previously stimulated with
VEGF (see chapter II).
The aim of the present study was to investigate the effect of HUVEC stimulated with
Ang1 or a combination of VEGF and Ang1 (VEGF/Ang1) on MSC differentiation in
vitro.
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Materials and Methods
Origins of human cells
Bone marrow aspirates were taken from patients undergoing routine
orthopedic surgery involving iliac crest exposure, after informed consent. Bone
marrow aspirates (20mL) were harvested into CPDA-containing Sarstedt monovettes
using a biopsy needle that was pushed through the cortical bone. Aspirates were
processed within 12-24 hours after harvesting.
Isolation and expansion of human MSC
Bone marrow aspirates were homogenized by pushing them a few times
through a syringe. The aspirate was then diluted 1:4 with IMDM (Gibco 42200-022)
containing 5% (v/v) FBS (Gibco 10270-106) and centrifuged at 200g for 5min at room
temperature (RT). The top layer (approx. 1cm) containing mostly fat tissue was
removed. Per 1mL of undiluted sample, 2.6mL of Ficoll (Histopaque-1077, Sigma
#1077-1) were pipetted into a 50mL Falcon tube and the aspirate was added
carefully on top of the Ficoll. After centrifugation at 800g for 20min at RT, the mono-
nucleated cells were collected at the interphase using a syringe. To 1mL of collected
interphase solution, 5mL of IMDM/5%FBS were added, the tube was gently mixed
and centrifuged at 400g for 15min at RT. The pellet was resuspended in the same
amount of IMDM/5%FBS, centrifuged again and resuspended in IMDM/5%FBS. Cell
number was determined using Methylene Blue in a hemocytometer. The cells were
seeded at densities of 8-10 *106 mono-nucleated cells per 150cm2 T-flask in IMDM
containing 10% FBS, nonessential amino acids (Gibco 11140-035) and PenStrep
(100U/mL, Gibco 15140-122). After 5 days, the monolayers were washed with
Tyrode’s balanced salt solution (TBSS) to remove non-adherent cells, and fresh
medium containing 5ng/mL b-FGF (R&D 233-FB) was added as previously reported
[25-27]. Medium was changed every 2-3 days and cells were subcultured 1:3 at sub-
confluence. The adherent cells after one subculture were termed Mesenchymal stem
Cells (MSC). Only cells between passages 2-4 (approx. 12-18 populations doublings)
were subsequently used [28].
Expansion of HUVEC
Primary Human Umbilical Vein Endothelial Cells (HUVEC) were purchased
from Cascade Biologics (cat# C-003-5C). The cells were expanded in IMDM
containing 10%FBS, nonessential amino acids, PenStrep, 20ug/mL ECGS (Sigma E-
Chapter III: Effect of Ang1 and a combination of VEGF/Ang1 on osteoblastic differentiation of MSC
63
2759) and 90ug/mL heparin (Sigma H-3149). Only cells between passages 2-4 were
subsequently used.
Stimulation of HUVEC with Ang1 or VEGF/Ang1
HUVEC were expanded in IMDM containing 10% FBS, nonessential amino
acids, 20ug/mL ECGS, 90ug/mL heparin and PenStrep. At about 75% of confluency,
100ng/mL Ang1 (R&D Systems 923-AN) or a combination of 100ng/mL Ang1 and
25ng/mL VEGF (Sigma V-7259) were added and the cells were stimulated for 3
days. The concentrations used in this study were chosen based on publications by
Hayes et al. (Ang1) [29] and Street et al. (VEGF) [30]. The HUVEC monolayers were
either used to produce HUVEC-conditioned medium (see Conditioned medium on
MSC cultures)) or were trypsinized and used for indirect contact co-cultures.
MSC cultures
MSC were seeded in 24-well plates (Falcon BD 353504) at a density of
20’000 cells/well in 1mL of medium and were left to attach for 2-3 hours. Culture
medium for the MSC culture systems contained IMDM, 10% FBS, nonessential
amino acids, 0.1mM ascorbic acid-2-phosphate (Sigma A-8960) and 10mM -
glycerophosphate (Sigma G-6251) with 10nM dexamethasone (osteogenic medium)
or without dexamethasone (non-osteogenic medium). Dexamethasone was
purchased at Sigma (D-2915). Media were changed twice a week.
Conditioned medium on MSC cultures
HUVEC-conditioned medium was produced by washing the VEGF/Ang1
stimulated (see section “Stimulation of HUVEC with Ang1 or VEGF/Ang1”) or non-
stimulated HUVEC monolayers twice with phosphate buffered saline (PBS) and then
culturing them for 24h in IMDM containing 10% FBS and PenStrep. After 24h, the
medium was removed, filtered (0.22µm), and stored at -20°C until used. This
conditioned medium was added in a 1:10 mixture to MSC monolayers cultured in
osteogenic or non-osteogenic medium in 24-well plates.
Indirect contact cultures of MSC and HUVEC (VEGF/Ang1 stimulated or non-
stimulated)
To MSC monolayers, VEGF/Ang1 stimulated (see section “Stimulation of
HUVEC with Ang1 or VEGF/Ang1”) or non-stimulated HUVEC were added in cell
culture inserts (0.4µm pore size, Falcon BD 353495) at a density of 10’000
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cells/insert. Fresh HUVEC were added once a week to the system to provide a fresh
supply of endothelial cell secreted factors. These experiments were also performed
in osteogenic or non-osteogenic medium.
Quantification of matrix mineralization using 45Ca2+ isotope
1.25µCi/mL of 45Ca2+ isotope (Amersham CES3) were added to each well and
the plates were incubated at 37°C for 6h [31]. The medium was removed and the
monolayers were washed 3x with IMDM to remove unincorporated 45Ca2+. Then
0.5mL of 70% formic acid were added to each well and the plates were incubated at
65°C for 1h. The formic acid solution was transferred to 3.5mL of scintillation liquid
(OptiPhase HiSafe’3 by Perkin Elmer) and the amount of radioactivity was measured
using a Wallac 1414 WinSpectral liquid scintillation counter.
Quantification of alkaline phosphatase activity
The medium was completely removed and the monolayers were washed
once with PBS. The cell layers were extracted by addition of 500µL of 0.1%Triton-X
in 10mM Tris-HCl (pH 7.4) and incubation at 4°C on a gyratory shaker for 2h (See
Sigma Technical Bulletin Procedure No.104). ALP activity was measured
colorimetrically by measuring the p-nitrophenol production during 15min incubation at
37°C with p-nitrophenyl phosphate as substrate (Sigma Kit Nr.104) on a Perkin Elmer
Bio Assay Reader HTS 7000.
RNA Isolation and Reverse Transcription
Monolayers were extracted using 500µL of TRI-Reagent (MRC Inc. TR-118)
with 5ul/mL of Polyacryl-carrier (MRC Inc. PC-152) for 10min at RT and transferred
to Eppendorf tubes. 150mL of 1-Bromo-3-Choro-Propane were added, the tubes
vortexed for 15sec and then centrifuged at 12’000g for 15min at 4°C. The colorless
layer on the top was transferred into a new tube and 750µL of isopropanol were
added, then the tube was centrifuged at 12’000g for 10min at 4°C. Sample
supernatants were removed and pellets were washed in 1mL of 75% EtOH by
vortexing and centrifuging at 10’000g for 5min at 4°C. Pellets were air-dried and re-
suspended in 30µL of DEPC-treated water. After 15min at 60°C, tubes were
immediately transferred to ice. The total RNA amount and purity was assessed by
measuring the absorbance at 260nm and 280nm. Reverse transcription was
performed using 1µg of total RNA sample, which was mixed with 2µL of 10x TaqMan
RT Buffer (500mM KCl, 100mM Tris-HCl, pH 8.3), 4.4µL of 25mM magnesium
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chloride, 4µL of dNTP mixture (2.5mM of each dNTP), 1µL of random hexamers
(50µM), 0.4µL of RNase inhibitor (20U/mL) and 0.5µL of MultiScribe Reverse
Transcriptase (50U/µL) (all from Applied Biosystems); DEPC-treated water was
added to bring the final reaction volume to 20µL. Reverse transcription was
performed using a Thermal Cycler 9600 by Applied Biosystems. cDNA samples were
appropriately diluted with Tris-EDTA buffer before being used for real-time RT PCR.
Real-time RT PCR
Oligonucleotide primers and TaqMan probes were designed using the Primer
Express Oligo Design software (Ver. 1.5, Applied Biosystems). The nucleotide
sequences were obtained from the GenBank database and the probes were
designed to overlap an exon-exon junction in order to avoid amplification of genomic
DNA. Primers and probes for amplification of 18S ribosomal RNA, used as
endogenous control, were from Applied Biosystems. All other primers and labeled
TaqMan probes were from Microsynth (Balgach, CH). TaqMan probes were labeled
with the reporter dye molecule FAM (6-carboxyfluorescein) at the 5´end and with the
quencher dye TAMRA (6-carboxy-N, N, N´, N´-tetramethylrhodamine) at the 3´end.
The PCR reaction mixture contained TaqMan Universal PCR master mix without
AmpErase UNG (Applied Biosystems), 900nM primers (forward and reverse), 250nM
TaqMan probe, and 2l of cDNA sample for a total reaction volume of 25l. PCR
conditions were 95°C for 10min, followed by 42 cycles of amplification at 95°C for
15sec and 60°C for 1min using the GeneAmp 5700 Sequence Detection System
(Applied Biosystems, Foster City, CA). Relative quantification of mRNA targets was
performed according to the comparative CT method with 18S ribosomal RNA as
endogenous control (ABI PRISM 7700 Sequence Detector User Bulletin (2), PE
Applied Biosystems 1997). For a list of primers and probes see chapter II, Table I.
Statistical analysis
The data are expressed as mean±SEM. Statistics were performed using the
non-parametric Mann-Whitney U-test, which compares the medians of two
independent distributions. P < 0.05 was considered statistically significant.
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Results
Experiments were performed with bone marrow aspirates from 3 different
donors (age range 39-66). The MSC used during the experiments were expanded in
standard medium supplemented with b-FGF to keep them in a tripotential state,
capable of differentiating along the osteogenic, chondrogenic and adipogenic
pathways [25, 26, 28].
In accordance to the results we obtained previously (see chapter II), there was no
difference in the inhibitory effect of HUVEC on MSC differentiation between indirect
co-cultures and HUVEC-conditioned medium cultures. The results presented in the
following paragraphs therefore are combined data from all experiments, independent
of the culture type (indirect co-cultures and HUVEC-conditioned medium).
Effect of (stimulated or unstimulated) HUVEC on MSC differentiation in non-
osteogenic medium
In non-osteogenic medium, HUVEC had no effect on MSC differentiation.
This pattern was not changed when HUVEC were previously stimulated with Ang1 or
a combination of Ang1 and VEGF (Figures 1 and 2 left side).
Effect of (stimulated or unstimulated) HUVEC on MSC differentiation in osteogenic
medium (OM)
As expected, osteogenic medium (OM) significantly up-regulated the
expression of several osteoblastic markers like calcium incorporation, ALP activity
and gene expression of Osx, BSPII, MMP-13, ON and Col1 when compared to MSC
in non-osteogenic medium (Figures 1-4). As shown before (see chapter II), the
addition of unstimulated HUVEC to MSC in OM results in a significant down-
regulation of osteoblastic markers, as prominently seen in significantly lowered
calcium incorporation, ALP activity and gene expression (Figures 1-4).
When HUVEC were previously stimulated with Ang1, they showed a very
comparable inhibitory effect on MSC differentiation as unstimulated HUVEC. The
same observation was made for HUVEC that were stimulated with a combination of
VEGF and Ang1 (VEGF/Ang1).
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Figure 1:
45
Ca
2+
incorporation by MSC at day 24: MSC in OM incorporated significantly more calcium
into their matrix than MSC in non-osteogenic medium (*), as expected. While endothelial cells (EC) did
not have an influence on MSC in non-osteogenic medium, they significantly down-regulated calcium
incorporation of MSC in OM. Stimulation of HUVEC with Ang1 or VEGF/Ang1 did not show any further
significant effect compared to unstimulated HUVEC (in non-osteogenic or osteogenic medium).
Figure 2: ALP activity of MSC at day 12: MSC in osteogenic medium (OM) showed significantly more
ALP activity that MSC in non-osteogenic medium (*), as expected. In non-osteogenic medium EC did
not show an effect, but in OM, ALP activity in MSC was significantly down-regulated by EC. Stimulation
of HUVEC with Ang1 or VEGF/Ang1 did not show any further significant effect compared to
unstimulated HUVEC (in non-osteogenic or osteogenic medium).
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Figure 3: Expression of the Osterix gene by MSC at day 24: While MSC in OM expressed Osx
prominently; MSC in non-osteogenic medium (*) did not. HUVEC significantly decreased Osx
expression of MSC in OM. Stimulation of HUVEC with Ang1 or VEGF/Ang1 did not have a significant
effect on Osx expression compared to unstimulated HUVEC.
Figure 4a-d: Gene expression of Collagen type I, BSP II, MMP-13 and Osteonectin at day 24: MSC in
OM expressed Col1, BSPII, MMP-13 and osteonectin prominently, while MSC in non-osteogenic
medium (*) showed significantly much lower levels. HUVEC significantly decreased the expression of
Col1, BSPII and MMP-13 by MSC in OM independent of being stimulated or not with Ang1 or
VEGF/Ang1.
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Discussion
Even though the generally accepted roles for VEGF and Ang1 during
angiogenesis are rather oppositely (destabilization versus maturation of blood
vessels), there are several recent in vivo studies that have shown Ang1 and VEGF
also to act synergistically during angiogenesis and vasculogenesis [19-24]. There is
very little literature about the in vitro effect of Ang1 on any cell type and its
interactions with VEGF. Huang et al. showed that Ang1 alone had no effect on
endothelial cell proliferation, but enhanced cell growth in the presence of VEGF [32].
Ang1 and VEGF have been shown to enhance endothelial cell migration and survival
in a dose-dependent manner [33, 34]. However, Ang1 opposes the effect of VEGF on
vascular permeability. In fact, Wang et al. have shown that VEGF-induced vascular
leak required the translocation and activation of protein kinase C and that this
pathway was efficiently blocked by Ang1 [35].
Since in an earlier study we were able to show that HUVEC had an inhibitory effect
on MSC differentiation in OM, and that this inhibitory effect could be amplified by
using VEGF-stimulated HUVEC (see chapter II), we were interested in investigating if
a similar effect could be observed with Ang1-stimulated or VEGF/Ang1-stimulated
HUVEC.
Our results showed, that Ang1-stimulated HUVEC were neither able to mimic the
inhibitory observed with VEGF-stimulated HUVEC, nor did it have a stimulatory effect
on osteogenic MSC differentiation. Interestingly, when MSC were exposed to
VEGF/Ang1-stimulated HUVEC, there was also no change in the expression levels of
osteoblastic markers compared to MSC exposed to unstimulated HUVEC. This
indicates that Ang1 might override the inhibitory effect of VEGF-stimulated HUVEC
on MSC differentiation.
Further studies will be necessary to evaluate whether higher concentrations
of Ang1 might be necessary to induce a detectable effect on MSC differentiation [33,
34]. In addition, experiments involving Ang2 alone or in combination with VEGF
should also be performed, since action of Ang2 is highly dependent on VEGF.
Finally, based on the findings described in chapter V, it should be as well considered
to repeat the 2D-experiments (including those with VEGF) in a 3D environment.
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Chapter IV
Definition of a PRP production protocol and the effect
of PRP on osteoblastic differentiation of MSC in vitro
Meury TR, Kupcsik L, Heini P, Becker S, Stoll T, Alini M
In this chapter, we focused on another important component of a bone construct: The
biological factors. We decided to investigate if platelet-rich plasma (PRP) due to its
autologous origin and its highly concentrated factor mixture could influence MSC
differentiation. In addition, due to its capacity to form a gel upon activation, PRP
could also serve as a matrix for cells. Since there was no consistent routine protocol
to produce PRP, we decided to first define a reliable PRP isolation and activation
protocol. Then we studied the influence of PRP on MSC differentiation into bone
forming cells.
This chapter is a manuscript submitted for publication to J Orthop Res.
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Introduction
Platelets play a pivotal role during wound healing. Upon being activated, they
adhere to the exposed sub-endothelium and form a clot by binding to circulating
fibrinogen molecules that cover the injured site and allow the healing process to
begin. This clot is stabilized by a thick fibrin-mesh, which forms under the control of
liver-produced thrombin. In addition, platelet activation and degranulation results in
the release of a high number of biological factors, which attract more platelets to the
site of injury, but also growth factors and cytokines that can target other cell types
(including PDGF, VEGF, IGF, EGF, FGF and TGF) [1, 2]. Many of those factors have
been known to play a direct role in normal bone turnover and in the events during
early bone healing [3]. This led to the idea to use platelets in bone repair in the form
of platelet-rich plasma (PRP) [4, 5]. PRP is autologous plasma that has a platelet
concentration above baseline (~1Mio platelets/µL vs. ~0.2Mio platelets/µL), but a
native fibrinogen concentration. A highly beneficial effect of PRP addition to bone
grafts, eventually in combination with mesenchymal stem cells is suspected.
However, the few studies performed using PRP in fracture repair resulted in only
moderately successful outcomes. Some groups have observed an increased bone
formation [4, 6-10], some an increased implant resorption [11], others have reported
improved osseointegration [10, 12, 13] or increased vascularization [11].
Nevertheless, several studies have shown no beneficial influence of PRP on bone
healing whatsoever [14-18].
The interpretation of all these studies is not simplified by the fact that they were
performed using many different species, including dog [11, 12, 14], rat [8, 17], mini-
pig [16, 19], goat [7], rabbit [6] and human [4, 9, 10, 15, 18] and many different defect
sites and types. Furthermore, there is great inconsistency in the techniques used for
PRP preparation. Some groups have used common protocols (1- or 2-step
centrifugations using normal lab equipment) [8, 11, 12], while others used
commercially available systems [19-21]. PRP preparations from these different
systems can hardly be compared, since the resulting platelet concentrations as well
as the growth factor concentrations released by the platelets are preparation
dependent [4, 22, 23]. Furthermore, while some groups activated the PRP (mostly by
addition of bovine Thrombin and CaCl2) [9, 11, 12, 16], others did not. In addition, a
few studies have shown, that PRP alone has a positive effect on bone healing, while
others only report a beneficial effect in combination with autologous precursor cells
[9, 11, 12].
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Our aim was to define a simple and quick procedure to produce PRP using
regular lab equipment. Additionally, we wanted to compare different activation
methods and evaluate their efficiency and efficacy. Also, there is a lack of in vitro
data concerning the influence of PRP on different cell types. A positive effect of PRP
on the proliferation [22, 24-28] and migration [27, 29] of several cells types including
MSC, stromal cells, osteoblastic cells or EC was reported quite consistently, but its
effect on cell differentiation remains unclear. We therefore evaluated the potential
effect of PRP on bone precursor cells in a controlled in vitro environment by
investigating its effect on human mesenchymal stem cell differentiation into
osteoblasts.
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Materials and Methods
Origin of bone marrow and blood aspirates
Bone marrow (60mL) and blood (100mL) aspirates in CPDA-containing
Sarstedt monovettes were received from patients undergoing routine orthopaedic
surgery involving iliac crest exposure, after informed consent (KEK Bern 126/03).
Blood aspirates were stored at RT under gentle agitation and bone marrow aspirates
were stored at 4°C under gentle agitation until processed within 24 hours after
harvesting. The platelets were counted using a Digitana Sysmex FS-3000.
MSC isolation and culture
Bone marrow aspirates were homogenized by pushing them a few times
through a syringe. The aspirate was then diluted 1:4 with IMDM (Gibco 42200-022)
containing 5% (v/v) FBS (Gibco 10270-106) and centrifuged at 200g for 5min at room
temperature (RT). The top layer (approx. 1cm) containing mostly fat tissue was
removed. To 1mL of undiluted sample, 2.6mL of Ficoll (Histopaque-1077, Sigma
#1077-1) were pipetted into a 50mL Falcon tube and the aspirate was added
carefully on top of the Ficoll. After centrifugation at 800g for 20min at RT, the
mononucleated cells were collected at the interphase using a syringe. To 1mL of
collected interphase solution 5mL of IMDM/5%FBS were added, the tube was gently
mixed and centrifuged at 400g for 15min at RT. The pellet was resuspended in the
same amount of IMDM/5%FBS, centrifuged again and resuspended in
IMDM/5%FBS. Cell number was determined using Methylene Blue in a
hemocytometer. The cells were seeded at densities of 8-10x106 mononucleated cells
per 150cm2 T-flask in IMDM containing 10% FBS, nonessential aminoacids (Gibco
11140-035) and PenStrep (100U/mL, Gibco 15140-122). After 5 days, the
monolayers were washed with Tyrode’s balanced salt solution (TBSS) to remove
non-adherent cells, and fresh medium containing 5ng/mL basic-FGF (R&D 233-FB)
was added as described previously [30-32]. Medium was changed every 3 days and
cells were subcultured 1:3 at sub-confluence. The adherent cells after one subculture
were termed mesenchymal stem cells (MSC). Cells between passages 2-4 were
subsequently used.
PRP preparation
The blood aspirates were transferred from the CPDA-cuvettes into 15mL
Falcon tubes, and were centrifuged at 200g for 30min at RT. The resulting plasma
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supernatants were pooled, transferred into a new 15mL Falcon tube, and centrifuged
at 2’000g for 5min at RT to get a platelet pellet. The resulting supernatant is called
platelet-poor plasma (PPP). Platelet-rich plasma (PRP) was produced by
resuspending the resulting pellet in the PPP (1/10th of the initial blood volume). Since
PRP has a tendency to gel, even when added in low concentrations to culture
medium, fibrinogen was removed by resuspending the platelet pellet in PBS (1/10th of
the initial blood volume) instead of plasma supernatant. This platelets-containing
PBS was termed platelet-released growth factors (PRGF). PRGF was stored at -
20°C until used to supplement MSC cultures. PRP was used immediately to evaluate
PRP activation efficiency.
PRP/PRGF activation
PRP or PRGF was activated using the following protocols:
Thrombin: 100U/mL of bovine Thrombin (Sigma T-4648) dissolved in PBS or 100mM
CaCl2 (10%) was added to the PRP or PRGF samples. The samples were kept at
37°C for 30-60min.
Freeze-Thaw cycles: PRP or PRGF in cryo-tubes (4.5mL, NUNC) were put in liquid
N2 for 1min to freeze “instantly”, then the tubes were transferred to a 37°C water-bath
to thaw for 5min. This procedure was repeated 5 times. After, the PRP or PRGF was
kept at 37°C for 30-60min. To some samples, 100mM CaCl2 (10%) was added
before the freeze-thaw cycles.
Fridge: The PRP or PRGF was frozen at -20°C for 30min, then kept at 37°C for 30-
60min. To some samples, 100mM CaCl2 (10%) was added before freezing.
Sonication: The PRP or PRGF was sonicated using a SONOPLUS-Ultraschall
Homogenisator (GM-70, UW-70, SH-70G) by Bandelin at 20 kHz for 10sec on ice,
and then kept at 37°C for 30-60min. To some samples, 100mM CaCl2 (10%) was
added before sonication.
Platelet activation efficiency by ELISA
To estimate platelet activation efficiency of the methods described above, the
release of PDGF-AB, -BB, and VEGF was determined. Following activation, the
samples were centrifuged at 18’000g for 2min to pellet debris and the gel that formed
after activation (only samples containing CaCl2). The resulting supernatant was
diluted 1:50 in PBS containing 0.1% BSA and human VEGF, PDGF-AB and -BB
protein content was measured using a DuoSet ELISA Development System by R&D
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Systems (PDGF-AB: DY222, PDGF-BB: DY220, VEGF: DY293B) on a Perkin Elmer
Bio Assay Reader HTS 7000.
MSC culture supplementation with PRGF
MSC were typsinized, washed, counted and seeded in 24-well (Falcon BD
353047) or 12-well plates (Falcon BD 353043) at densities of 10’000 to 15’000
cells/cm2 and were left to attach over night in IMDM supplemented with 10% FBS.
Culture medium during the experiments consisted of IMDM, 10% FBS, nonessential
amino acids, 0.1mM ascorbic acid-2-phosphate (Sigma A-8960) and 10mM -
glycerophosphate (Sigma G-6251). To some cultures (positive control), 10nM
dexamethasone (Sigma D-2915) was added. Media were changed twice a week.
Some cultures were supplemented with 1, 5, 10 or 20% activated PRGF (containing
no CaCl2).
45Ca incorporation assay
1.25µCi/mL of 45Ca2+ isotope (Amersham CES3) were added to each well and
the plates were incubated at 37°C o/n. The medium was removed and the cell
monolayers were washed 3x with IMDM to remove unincorporated 45Ca2+. Then
0.5mL of 70% formic acid were added to each well and the plates were incubated at
65°C for 1h. The formic acid solution was transferred to a scintillation tube containing
3.5mL of scintillation liquid (OptiPhase HiSafe’3 by Perkin Elmer) and the amount of
radioactivity was measured using a Wallac 1414 WinSpectral liquid scintillation
counter.
Van Kossa staining
MSC monolayers were rinsed with TBSS. Fresh silver nitrate solution (5%)
was added and the cells were exposed to strong light for 20min. After rinsing 3 times
with distilled water, the cells were incubated in fresh 5% sodium thiosulfate for 10min,
before being rinsed again 3 times with distilled water. Then the cells were incubated
in 0.1% nuclear fast red solution for 10min, before being rinsed again with distilled
water. Samples were left in distilled water and pictures were taken immediately.
ALP activity assay
The medium was completely removed and the MSC monolayers were
washed once with PBS. The cell layers were extracted by addition of 500µL of
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0.1%Triton-X in 10mM Tris-HCl (pH 7.4) and incubation at 4°C on a gyratory shaker
for 3h (See Sigma Technical Bulletin Procedure No.104). ALP activity was measured
colorimetrically by measuring the p-nitrophenol production during a 15min incubation
at 37°C with p-nitrophenyl phosphate as substrate (Sigma Kit No.104) on a Perkin
Elmer Bio Assay Reader HTS 7000.
RNA isolation and reverse transcription
Monolayers were extracted using 500µL of TRI-Reagent (MRC Inc. TR-118)
with 5ul/mL of polyacryl-carrier (MRC Inc. PC-152) for 10min at RT and transferred to
Eppendorf tubes. 150mL of 1-Bromo-3-Choro-Propane were added, the tubes
vortexed for 15sec and then centrifuged at 12’000g for 15min at 4°C. The colorless
layer on the top was transferred into a new tube and 750µL of isopropanol were
added, then the tube was centrifuged at 12’000g for 10min at 4°C. Sample
supernatants were removed and pellets were washed in 1mL of 75% EtOH by
vortexing and centrifuging at 10’000g for 5min at 4°C. Pellets were air-dried and re-
suspended in 30µL of DEPC-treated water. After 15min at 60°C, tubes were
immediately transferred to ice. The total RNA amount and purity was assessed by
measuring the absorbance at 260nm and 280nm. Reverse transcription was
performed using 1µg of total RNA sample, which was mixed with 2µL of 10x TaqMan
RT Buffer (500mM KCl, 100mM Tris-HCl, pH 8.3), 4.4µL of 25mM magnesium
chloride, 4µL of dNTP mixture (2.5mM of each dNTP), 1µL of random hexamers
(50µM), 0.4µL of RNase inhibitor (20U/mL) and 0.5µL of MultiScribe Reverse
Transcriptase (50U/µL) (all from Applied Biosystems); DEPC-treated water was
added to bring the final reaction volume to 20µL. Reverse transcription was
performed using a Thermal Cycler 9600 (by Applied Biosystems). cDNA samples
were appropriately diluted with Tris-EDTA buffer before being used for real-time RT
PCR.
Real-time RT PCR
Oligonucleotide primers and TaqMan probes were designed using the Primer
Express Oligo Design software (Ver. 1.5, Applied Biosystems). The nucleotide
sequences were obtained from the GenBank database and the probes were
designed to overlap an exon-exon junction in order to avoid amplification of genomic
DNA. Primers and probes for amplification of 18S ribosomal RNA, used as
endogenous control, were from Applied Biosystems. All other primers and labeled
TaqMan probes were from Microsynth (Balgach, CH). TaqMan probes were labeled
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with the reporter dye molecule FAM (6-carboxyfluorescein) at the 5´end and with the
quencher dye TAMRA (6-carboxy-N, N, N´, N´-tetramethylrhodamine) at the 3´end.
The PCR reaction mixture contained TaqMan Universal PCR master mix without
AmpErase UNG (Applied Biosystems), 900nM primers (forward and reverse), 250nM
TaqMan probe, and 2l of cDNA sample for a total reaction volume of 25l. PCR
conditions were 95°C for 10min, followed by 42 cycles of amplification at 95°C for
15sec and 60°C for 1min using the GeneAmp 5700 Sequence Detection System
(Applied Biosystems, Foster City, CA). Relative quantification of mRNA targets was
performed according to the comparative CT method with 18S ribosomal RNA as
endogenous control (ABI PRISM 7700 Sequence Detector User Bulletin (2), PE
Applied Biosystems 1997). The sequences of the primer and probes used are shown
in Table I.
Statistics
All results are shown as mean±SEM. Statistical analyses were performed
using the non-parametric Mann-Whitney U-test, which compares the medians of two
independent distributions. P < 0.05 was considered to be statistically significant.
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Table I. Primers and Probes for Real-Time RT-PCR
Target Gene Sequence (5’  3’)
Collagen I
Forw CCC TGG AAA GAA TGG AGA TGA T
Rev ACT GAA ACC TCT GTG TCC CTT CA
Probe CGG GCA ATC CTC GAG CAC CCT
Osteonectin
Forw ATC TTC CCT GTA CAC TGG CAG TTC
Rev CTC GGT GTG GGA GAG GTA CC
Probe CAG CTG GAC CAG CAC CCC ATT GAC
MMP-13
Forw CGG CCA CTC CTT AGG TCT TG
Rev TTT TGC CGG TGT AGG TGT AGA TAG
Probe CTC CAA GGA CCC TGG AGC ACT CAT GT
BMP-2
Forw AAC ACT GTG CGC AGC TTC C
Rev CTC CGG GTT GTT TTC CCA C
Probe CCA TGA AGA ATC TTT GGA AGA ACT ACC AGA AAC TG
Osteocalcin
Forw AAG AGA CCC AGG CGC TAC CT
Rev AAC TCG TCA CAG TCC GGA TTG
Probe ATG GCT GGG AGC CCC AGT CCC
Osteopontin
Forw CTC AGG CCA GTT GCA GCC
Rev CAA AAG CAA ATC ACT GCA ATT CTC
Probe AAA CGC CGA CCA AGG AAA ACT CAC TAC C
Runx2
Forw AGC AAG GTT CAA CGA TCT GAG AT
Rev TTT GTG AAG ACG GTT ATG GTC AA
Probe TGA AAC TCT TGC CTC GTC CAC TCC G
BSP II
Forw TGC CTT GAG CCT GCT TCC
Rev GCA AAA TTA AAG CAG TCT TCA TTT TG
Probe CTC CAG GAC TGC CAG AGG AAG CAA TCA
Osx and Dlx5:
Primers and Probes: Assays-On-Demand by Applied Biosystems
Osx: Hs00541729_m1
Dlx5: Hs00193291_m1
Probes were modified at the 5’ end with the FAM fluorescent dye (6-
carboxyfluorescein) and at the 3’ end with the TAMRA fluorescent dye (6-
carboxy-N,N,N’,N’-tetramethylrhodamine). Assay-On-Demand probes had a
non-fluorescent quencher at the 3’end.
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Results
The average age of the patients in this study was 49 years (youngest 28,
oldest 79). There were no obvious differences in the results obtained from the
different donors (12 males, 4 females).
PRP production
Preparation: Two different common storage temperatures were tested for the blood
aspirates, 4°C and room temperature (24°C). Aspirates that were stored at 24°C over
night showed significantly higher intact platelet numbers in blood, plasma and PRP
than aspirates that were stored at 4°C over night (Figure 1a). Also PDGF-AB and –
BB protein levels were approximately 2.5x higher when the blood was stored at 24°C
rather than at 4°C (Figure 1b).
Figures 1a/b: Comparison of storage temperatures for PRP (n=6): PRP stored at room temperature
over night showed significantly higher (P<0.05) numbers of undamaged platelets than when stored at
4°C (a). Also, PDGF levels released by activated platelets that were stored at room temperature were
significantly higher (P<0.05) than the levels released by platelets stored at 4°C (b).
Different combinations of centrifugation speeds were tested to obtain an optimal
protocol for PRP preparation. A single-step protocol (150g, 10min) was compared to
two 2-step protocols (30min at 200g followed by 5min at 200g and 30min at 200g
followed by 5min at 2’000g). To better estimate the efficiency of the 2-step protocols,
the number of the remaining platelets in PPP was also determined. A first
centrifugation step at 200g for 30min at RT, followed by a second centrifugation step
at 2’000g for 5min at RT showed the best platelet yield (Figure 2).
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Figure 2:
Comparison of
different PRP-
preparation protocols
(n=6): Numbers of
platelets were
measured before
and after different
centrifugations. PRP-
preparation using
two consecutive
centrifugation steps
(200g for 30min
followed by 2’000g
for 5min) showed the
highest platelet yield
in PRP and almost
no platelet leftovers
in PPP.
PRP/PRGF Activation: Platelet activation was estimated by measuring the release of
PDGF-AB, PDGF-BB and VEGF protein by the platelets upon appliance of different
activation methods, without addition of CaCl2 to avoid gel formation. The release of
PDGF-AB and –BB upon activation was comparable for all activation methods
(Figure 3). VEGF levels were extremely low and often not detectable at all (data not
shown). When the same activation methods were used in the presence of CaCl2, gels
formed within 5-30min in all samples. The samples were then centrifuged at 18’000g
for 3min to pellet the gel and the supernatant was used for the ELISA. Interestingly,
PDGF levels were significantly lower in the presence of CaCl2 than without (data not
shown).
Figure 3:
Comparison of
different platelet
activation methods
(n=5): PRP activation
efficiency was
determined by the
PDGF levels after
activation. All tested
methods resulted in
similar PDGF levels,
suggesting that all
activation methods
are equally effective.
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There was no correlation between the platelet number in blood or PRP before
activation and the resulting protein levels measured after activation (data not shown).
Effect on MSC
The activated PRP was centrifuged at 18’000g for 10min at RT to pellet the
gel and the supernatant was used to supplement the culture medium at a 1:10 ratio.
After the addition of PRP, the MSC culture medium showed again a strong tendency
to coagulate after a few hours, even without CaCl2 addition. We therefore
supplemented MSC medium with PRGF (no fibrinogen), which did not show any
coagulation. Comparison of the PDGF-AB and –BB levels in PRP and PRGF showed
also very similar values, allowing us to conclude that the effect of PRGF on MSC
should be analogous to that of PRP. So all experiments described below were
carried out using PRGF (Figure 4).
Figure 4:
Comparison of PRP
and PRGF protein
levels upon
activation (n=6):
PRP and PRGF
were activated using
the sonication and
the fridge methods
and PDGF-AB and
–BB levels were
determined. There
was no significant
difference between
PRP and PRGF.
This justifies the
replacement of PRP
by PRGF as cell
culture medium
supplement.
Ca incorporation
The effect of PRGF on matrix mineralization by MSC was estimated by
measuring 45Ca2+ incorporation into the MSC extracellular matrix (Figure 5) and by
Van Kossa staining (Figure 6). MSC grown in medium supplemented with PRGF
showed an up-regulation of 45Ca2+ incorporation by up to 400-fold compared to
unsupplemented MSC. This effect was independent of the activation method used
and was significantly higher than the effect of dexamethasone (Figure 5).
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Van Kossa staining of MSC monolayers at day 14 showed slightly elevated calcium
deposition in cultures supplemented with Dex (middle), compared to MSC grown
without Dex (left). Supplementation with PRGF (right) resulted in a significant up-
regulation of calcium deposition by MSC (Figure 6).
Figure 5:
45
Ca
2+
incorporation by
MSC at days 14 and
21, relative to
unsupplemented (no
PRGF, no Dex) MSC
(n=9): MSC
supplemented with Dex
M( SC +Dex) served as
a positive control.
Supplementation of
MSC with PRGF
resulted in significantly
higher calcium
incorporation than MSC
lone, even more than
MSC +Dex. This result
was independent of the
RGF activation
method used.
Figure 6: Van Kossa staining of MSC monolayers at day 14: left: unsupplemented MSC, middle: MSC
supplemented with Dex, right: MSC supplemented with PRGF.
P<0.05
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ALP Activity
As expected, ALP activity in MSC supplemented with Dex was significantly
higher than in MSC cultured without supplementation. Interestingly, PRGF did not
show any effect on ALP activity of MSC (Figure 7).
Figure 7:
ALP activity of MSC (n=4):
MSC supplemented with
Dex (MSC +Dex) showed
significantly elevated ALP
activity compared to
unsupplemented MSC
(MSC). Supplementation of
MSC with PRGF (MSC
+PRGF) showed no effect
of ALP activity.
Gene expression
The change in expression levels of several osteoblastic marker genes by
MSC was analyzed. PRGF significantly increased the gene expression of Col1, BSP,
ON, OP and BMP-2 in MSC at day 28 compared to MSC without PRGF (Figure 8).
MMP-13 was expressed at very low levels in all cultures but was increased
significantly by PRGF (data not shown). Interestingly, there was no significant effect
of PRGF on the expression of the osteoblastic transcription markers Dlx5, Runx2 and
Osterix (data not shown).
Figure 8:
Gene expression of typical
osteoblastic marker genes
by MSC at day 28 (n=6):
The type I collagen (Col1),
bone sialoprotein (BSP),
osteonectin (ON),
osteopontin (OP) and bone
morphogenetic protein 2
(BMP-2) were significantly
(P<0.05) up-regulated in
MSC supplemented with
PRGF.
Data is expressed as
mRNA levels in
MSC+PRGF relative to
unsupplemented MSC.
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Dose dependency
We also evaluated how different concentrations of PRGF would affect MSC
differentiation by measuring 45Ca2+ incorporation. MSC culture media supplemented
with 1% or 5% PRGF showed only a small increase (up to 2.6-fold) in 45Ca2+
incorporation compared to the control. At 10% PRGF, a significant up-regulation
(average of 288-fold) of 45Ca2+ incorporation was observed, which did not show any
further increase with 20% PRGF (Figure 9).
Figure 9:
Dose dependency assay
using 1%, 5%, 10% and 20%
(v/v) PRGF in MSC culture
medium (n=3):
Supplementation of MSC
culture medium with 1% and
5% PRGF did not result in a
significant up-regulation of
calcium incorporation.
However supplementation
with 10% PRGF resulted in
significant up-regulation of
calcium incorporation.
Addition of 20% PRGF did not
result in a further up-
regulation.
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Discussion
The aim of this study was to evaluate different protocols to isolate and
activate platelet-rich plasma. Furthermore, we wanted to assess the possible
influence of PRP on MSC differentiation in vitro. Regarding our first aim, our results
showed that blood aspirates are best stored at room temperature until PRP is
isolated. In fact, if PRP is conserved at 4°C for 24h, we observed a significant drop in
platelet numbers and following activation, also lower PDGF protein levels. A possible
explanation for this is that platelets have been shown to be activated upon exposure
to 4°C [33-36] and that therefore the released factors could be lost during the
subsequent PRP preparation. This also correlates with the common storage
temperature of platelet concentrates at blood banks (20-24°C). PRP can easily be
prepared by two consecutive centrifugation steps using 200g for 30min, followed by
2’000g for 5min, both at room temperature. It is very important to collect the entire
plasma layer after the first centrifugation step, especially the lower parts, otherwise a
large percentage of the platelets will be lost due to their close proximity to the
leukocyte layer. The second centrifugation step should be rather short, 5min in our
case, in order to facilitate the resuspention of the platelet pellet. Activation of the PRP
is necessary to release the stored factors. This can be achieved by different
methods, all of which resulted to be equivalent. The use of bovine thrombin for PRP
activation is a widely used but rather controversial method due to its animal origin.
On the other hand, the amount and the speed of PRP-gel formation can be very well
controlled by this method. Repeated freeze-thaw cycles in liquid N2 have the
advantage of not using any debatable chemicals for activation, the disadvantage is
that it is rather time consuming. Freezing the PRP at -20°C for >30min gives
comparable results and is an easier PRP activation method, as is sonication. Overall,
our activation method of choice was sonication, mainly due to the speed advantage.
However, we realize that in a hospital setup, other methods might be preferred.
Addition of CaCl2 to the above activation methods leads to gelling of the PRP
preparations in a controlled manner, normally within 30-60min. The use of CaCl2
during platelet activation can have both advantages and disadvantages, depending
on the application. In in vivo applications, the gelling effect is clearly useful. A PRP
gel, implanted alone or in combination with cells seeded (or not) on a suitable
scaffold, is not only a source of beneficial growth factors and cytokines, but it might
also provide a matrix support (fibrin mesh) that could facilitate cell adhesion and cell-
matrix interactions. However, for 2D in vitro studies, the gelling effect of PRP was a
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major problem. We observed gelling of the PRP-supplemented MSC culture medium
after less than 36h, even though the PRP preparation was activated without the
addition of CaCl2. We therefore had to supplement our culture media with platelet-
released growth factors in PBS, thus avoiding the presence of fibrinogen and the
subsequent gelling of the culture media. We validated this approach by showing that
PRP and PRGF have comparable levels of PDGF-AB and –BB after activation by
sonication and freezing at -20°C.
To estimate the effect that platelet released growth factors have on MSC
differentiation towards the osteoblastic phenotype, we measured typical osteoblastic
markers, including matrix mineralization, ALP activity and the expression of
characteristic osteoblastic genes. The expression of the typical osteoblastic marker
genes Col1, BSP, ON, OP and BMP-2 and MMP-13 was enhanced by PRGF
suggesting that MSC were induced to differentiate into osteoblasts. As expected, the
addition of the steroid dexamethasone also significantly increased calcium
incorporation, but surprisingly to a lesser extent than PRGF. While calcium
incorporation was greatly increased by the addition of PRGF after 21 days, PRGF
had no effect on ALP activity. Studies have shown that BMP-2 and Dex highly
increase matrix mineralization in human marrow-derived cells, but only Dex and not
BMP-2 increases also ALP activity [37, 38]. We therefore suggest that PRGF is able
to induce osteoblastic differentiation of MSC through a BMP-2 mediated pathway.
This is also supported by highly up-regulated BMP-2 gene expression levels
observed in PRGF-stimulated cultures.
In summary, we defined a quick, simple and yet efficient protocol for the
production of platelet-rich plasma using common lab equipment. All the tested
activation methods showed to be equally efficient, therefore the activation protocol
can be chosen depending on the needs and on the available equipment. More
importantly, we were able to show that PRP in vitro is able to induce MSC to
differentiate into an osteoblastic phenotype. This osteoinductive potential of PRP
might be useful to improve and accelerate bone healing, especially following
infection, tumor resection, open fractures or non-unions, all of which are still major
problems in today’s orthopaedic clinics.
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Chapter V
In vitro evaluation of an endothelialized tissue
engineered 3D-construct for bone repair
Meury TR, Alini M
Finally, in the last experimental part of the thesis we combined all the observations
and findings obtained and described in the previous chapters to develop a construct,
which might serve as a bone graft for future in vivo experiments. By combining
osteoblastic precursors, endothelial cells as well as PRP, we believe to have the
necessary elements needed to accelerate the formation of blood vessels within the
graft when implanted in an animal model of large bone defects, as well as the
appropriate stimuli to induce MSC to differentiate into bone forming cells.
This chapter, following repetition of certain experiments, will lead to a manuscript to
be submitted to Tissue Engineering.
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Introduction
Autologous bone grafting is the current golden standard for the repair of large
bone defects, despite its obvious drawbacks like limited availability of grafting
material and donor site morbidity [1-4]. Possible alternatives are allografts or
xenografts, but in addition to the problematic ethical aspects, these kinds of grafts
also have serious limitations, like the risk of infections and possible immune
reactions. Due to these problems with autografts, allografts and xenografts,
researchers in the area of bone repair have explored alternative solutions. Calcium
phosphate and hydroxyapatite based materials as well as polymer scaffolds have
shown some interesting osteoconductive properties [5-10]. Nevertheless, the lack of
osteoinductive potential very often prevents the perfect healing of the defect treated
only with alloplastic materials. Many studies have shown that the lack of
osteoinductive potential of these scaffolds can be partly overcome by seeding
osteoblastic precursor cells into the scaffold prior to implantation. This approach
resulted in a significant improvement of the healing process [6, 11-19]. However, not
all problems have been solved yet and a major one remaining is the insufficient
vascularization of the central part of such grafts when used in large bone defects
[11].
We have therefore focused our studies on the interactions of endothelial cells and
bone precursor cells. Our previous study showed that endothelial cells could
modulate mesenchymal stem cell differentiation, by keeping them in a pre-
osteoblastic state, while increasing their osteogenic potential (see chapter II). So the
use of a combination of endothelial cells and bone precursor cells in an alloplastic
bone construct could have a positive effect on the vascularization of the whole
construct.
Early events during natural bone repair include the formation of a blood clot at the
damaged site resulting in the attraction of many different cell types to the repair site.
This initial recruitment is mainly mediated by factors released from the activated
platelets present within the blood clot. In an earlier study (see chapter IV), we were
able to show that activated platelet-rich plasma (PRP) has the potential to strongly
promote osteoblastic differentiation of mesenchymal stem cells (MSC) in monolayer.
This osteoblastogenesis-promoting property of PRP combined with its ability to form
a gel upon activation as well as its richness in factors known to be involved in
angiogenesis strongly suggest, that PRP could represent the ideal autologous
biological stimuli necessary to improve angiogenesis and bone formation within a
construct seeded with the appropriate cells.
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We therefore studied the potential of a complex 3D construct composed of a
polyurethane scaffold seeded with MSC and EC embedded in a PRP gel in a
controlled in vitro environment.
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Endothelial cell markers
During this study, we evaluated several markers related to angiogenesis and
endothelial differentiation:
Von Willebrand factor (vWf, factor VIII-related antigen) is a cell surface glycoprotein
necessary for adhesion of platelets to the sub-endothelium upon vascular rupture
[20]. It also plays an important role in the interactions between endothelial cells and
the surrounding matrix [21]. vWf is often used as an endothelial differentiation marker
due to its very high specificity and to its increasing expression by endothelial cells
during maturation of the microvasculature [22].
VE-cadherin (CDH5, CD144) is also an endothelial surface marker involved in cell-
cell adhesion through intercellular junctions. It is specific for vascular endothelium
and is suggested to be a later marker of endothelial cell differentiation in vitro [23].
EGFL7 (EGF-like domain 7, VE-statin) is expressed at high levels by endothelial cells
during vascular remodeling and is down-regulated in mature vessels [24].
MMP-2 (72kDa-Gelatinase, Gelatinase A) and MMP-9 (92kDa-Gelatinase,
Gelatinase B) are extracellular endopeptidases that are highly involved in
angiogenesis. Together they are able to break down most extracellular matrix
components including the collagen types I, II, IV, X, as well as gelatin, elastin,
aggrecan, fibronectin, osteonectin and laminin [25-30] . They are suggested to play a
major role in tissue remodeling and repair as well as in tumors metastases. MMP-2
has also been shown to be able to activate MMP-9 and MMP-13 [31, 32].
VEGF receptors-1 (Flt-1), -2 (Flk-1, KDR) and -3 (Flt-4) are all closely related
receptor tyrosine kinases expressed in the vascular endothelium. VEGFR-2 seems to
mediate the major actions of VEGF, whereas VEGFR-1 is suggested to have a
negative role (either as a decoy receptor, or by suppressing signaling through
VEGFR-2). VEGFR-3 is the least understood VEGF receptor and may be important
during blood vessel development, but also seems to be critical for lymphatic vessel
formation.
Tie1 and Tie2 (TEK) are receptors for angiopoietins (receptor tyrosine kinases). They
are selectively expressed in the vascular endothelium [33, 34]. All known
angiopoietins bind primarily to Tie2 while the role of Tie1 is still unclear. Both are
highly expressed in EC during vessel formation and remodeling.
Platelet-derived growth factor receptor beta polypeptide (PDGFRB, CD140B) is a
receptor for PDGF, which has been reported to promote angiogenesis.
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Endothelin-1 (ET-1) is a potent vasoconstrictor known to be involved in the
interactions of endothelial cells and osteoblastic cells. ET-1 has been shown to
enhance proliferation and differentiation of osteoprogenitors cells [35].
Laminin: Laminin is an important component of the basal lamina. Laminin is linked to
the vimentin protein located in the cytoskeleton of endothelial cells, which appears to
play an important role in endothelial cell migration and in blood vessel
morphogenesis [36].
CD31 (PECAM-1) is an integral membrane protein that mediates cell-to-cell
adhesion. CD31 is expressed constitutively on the surface of adult and embryonic
endothelial cells and is weakly expressed on platelets. CD31 mediated endothelial
cell-cell interactions are involved in angiogenesis [37].
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Materials and Methods
Origins of human cells
Aspirates of bone marrow and blood were obtained from patients undergoing
hip surgery after informed consent (KEK Bern 126/03). Fifty milliliters of bone marrow
and 100mL of blood aspirates were collected into CPDA-containing Sarstedt
monovettes. Bone marrow aspirates were stored at 4°C and blood at room
temperature (RT). Samples were processed within 24h after harvesting.
Isolation and expansion of human MSC
After homogenization of the bone marrow aspirates by pushing them a few
times through a syringe, they were diluted 1:4 with IMDM (Gibco 42200-022)
containing 5% (v/v) FBS (Gibco 10270-106) and were centrifuged at 200g for 5min at
room temperature (RT). The fat-containing top layer was removed. Per 1mL of
undiluted sample, 2.6mL of Ficoll (Histopaque-1077, Sigma #1077-1) were pipetted
into a 50mL Falcon tube and the aspirate was added carefully on top of the Ficoll.
After centrifugation at 800g for 20min at RT with lowest possible brake-settings, the
mono-nucleated cells were collected at the interphase using a syringe. To 1mL of
collected interphase solution, 5mL of IMDM/5%FBS were added, the tube was gently
mixed and centrifuged at 400g for 15min at RT. The resulting pellet was resuspended
in the same amount of IMDM/5%FBS, centrifuged again and resuspended in
IMDM/5%FBS. Cell number was determined using Methylene Blue in a
hemocytometer. The cells were seeded at densities of 15-20x106 mono-nucleated
cells per 300cm2 T-flask in IMDM containing 10% FBS, nonessential amino acids
(Gibco 11140-035) and PenStrep (100U/mL, Gibco 15140-122). After 5 days, the
monolayers were washed with Tyrode’s balanced salt solution (TBSS) to remove
non-adherent cells, and fresh medium supplemented with 5ng/mL b-FGF (R&D 233-
FB) was added [38-40]. Medium was changed twice a week and cells were
subcultured 1:4 at sub-confluence. The adherent cells after one subculture were
termed Mesenchymal stem Cells (MSC). Only cells between passages 2-5 (approx.
12-22 populations doublings) were subsequently used [41].
Expansion of HUVEC
Primary human umbilical vein endothelial cells (HUVEC) were purchased
from Cascade Biologics (cat# C-003-5C). The cells were expanded in M200
(Cascade M200-500) supplemented with low serum growth supplement (S-003-10),
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which contains fetal bovine serum, hydrocortisone, human epidermal growth factor,
b-FGF and heparin. Cells were subcultured 1:4 at sub-confluence and passages 2-5
were subsequently used.
3D-constructs
Isosorbide polyurethane scaffolds (termed IsoK-40 and IsoK-43) were
prepared using a combined salt leaching – phase-inverse technique. Salt crystals
with particle sizes in the range of 200 – 600µm were used as a porogen. IsoK-40 and
-43 were identical, except that IsoK-43 additionally contained 25% of nano-size
hydroxyapatite with an average particle size of 20nm (Advanced Biomaterials, Inc.,
Berkeley, USA). The scaffolds had interconnected pores with average pore size of
500µm and pore to volume ratio of 90%. The presence of hydroxyapatite had no
effect on the porous structure of the sponges. The scaffolds were gas-sterilized prior
to be used.
PRP production
The blood aspirates were transferred from the CPDA-cuvettes into 15mL
Falcon tubes, and were centrifuged at 200g for 30min at RT. The resulting plasma
supernatants were pooled, transferred into a new 15mL Falcon tube, and centrifuged
at 2’000g for 5min at RT to get a platelet pellet. Platelet-rich plasma (PRP) was
produced by resuspending the resulting pellet in the remaining plasma supernatant
(1/10th of the initial blood volume). PRP was used stored at -20°C until used.
Cell seeding on scaffolds
After sterilization, the scaffolds were degassed in IMDM under vacuum over
night. The next day the liquid in the scaffolds was removed using vacuum and the
scaffolds were ready to be loaded with cells:
MSC or HUVEC were trypsinized, washed twice (centrifuging at 380g for 10min at
RT and resuspending in IMDM/FBS) and counted using Trypan Blue and a
hemocytometer. After counting, the cells were centrifuged and resuspended in PRP
(see “PRP production”) or fibrin sealant (Baxter Biosurgery, Vienna) at a
concentration of 5x106 cells/150µL. Fibrin sealant consisted of the fibrinogen
component (diluted to final concentration 3.3mg/mL using proprietary dilution buffers
provided by Baxter) and a thrombin component. Just before being loaded into the
scaffolds, the cell/fibrin suspension was activated by addition of 15µL of the thrombin
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component (final concentration 5U/mL). Cells in PRP were activated using 15µL of
bovine thrombin (final concentration 5U/mL, Sigma T-4648) dissolved in PBS or
100mM CaCl2 (10%). Quickly, the cell/fibrin or cell/PRP was pipetted into a sterile
Eppendorf tube cap (cut off from the Eppendorf tube and turned upside down) and
the scaffold was added on top of it. Since the inner part of the cap has a diameter
just slightly larger than the scaffold, it provides a loading chamber that seals all sides
of the scaffold but the top. So by carefully adding a bit of pressure to the top of the
scaffold using forceps, the cell suspension located below the scaffold was sucked
into the scaffold upon pressure release. Due to the thrombin component, the
suspension gelatinized in the scaffold within a few minutes. The scaffolds were
incubated in the Eppendorf tube caps for 30min at 37°C. The samples were then
moved to 6-well plates and were cultured in IMDM containing 10% FBS, nonessential
amino acids, PenStrep and 500KIU/mL Aprotinin from bovine lung (Fluka #10820) to
avoid fibrin gel degradation [42]. Sandwich constructs were kept together using
PTFE-rings (polytetrafluoroethylene = Teflon®).
Polyurethane scaffolds fixated by PTFE-rings
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RNA Isolation and Reverse Transcription
The scaffolds containing cells in fibrin or PRP were pulverized in liquid
nitrogen and total mRNA was extracted using 1mL of TRI-Reagent (MRC Inc. TR-
118) with 5µL/mL of Polyacryl-carrier (MRC Inc. PC-152) in Eppendorf tubes. 150mL
of 1-Bromo-3-Choro-Propane were added, the tubes were vortexed for 15sec and
then centrifuged at 12’000g for 15min at 4°C. The colorless layer on the top was
transferred into a new tube and 750µL of isopropanol were added, then the tube was
centrifuged at 12’000g for 10min at 4°C. Sample supernatants were removed and
pellets were washed in 1mL of 75% EtOH by vortexing and centrifuging at 10’000g
for 5min at 4°C. Pellets were air-dried and re-suspended in 30µL of DEPC-treated
water. After 15min at 60°C, tubes were immediately transferred to ice. The total RNA
amount and purity was assessed by measuring the absorbance at 260nm and
280nm. Reverse transcription was performed using 1µg of total RNA sample, which
was mixed with 2µL of 10x TaqMan RT Buffer (500mM KCl, 100mM Tris-HCl, pH
8.3), 4.4µL of 25mM magnesium chloride, 4µL of dNTP mixture (2.5mM of each
dNTP), 1µL of random hexamers (50µM), 0.4µL of RNase inhibitor (20U/mL) and
0.5µL of MultiScribe Reverse Transcriptase (50U/µL) (all from Applied Biosystems);
DEPC-treated water was added to bring the final reaction volume to 20µL. Reverse
transcription was performed using a Thermal Cycler 9600 by Applied Biosystems.
cDNA samples were diluted to 250µL with Tris-EDTA buffer before being used for
real-time RT PCR.
Real-time RT PCR
Oligonucleotide primers and TaqMan probes were either purchased from
Applied Biosystems (Assay-On-Demand) or were designed using the Primer Express
Oligo Design software (Ver. 1.5, Applied Biosystems). The nucleotide sequences
were obtained from the GenBank database and the probes were designed to overlap
an exon-exon junction in order to avoid amplification of genomic DNA. Primers and
probes for amplification of 18S ribosomal RNA, used as endogenous control, were
from Applied Biosystems. All other primers and labeled TaqMan probes were from
Microsynth (Balgach, CH). TaqMan probes were labeled with the reporter dye
molecule FAM (6-carboxyfluorescein) at the 5´end and with the quencher dye
TAMRA (6-carboxy-N, N, N´, N´-tetramethylrhodamine) at the 3´end. The PCR
reaction mixture using self-designed primers and probes contained TaqMan
Universal PCR master mix without AmpErase UNG (Applied Biosystems), 900nM
primers (forward and reverse), 250nM TaqMan probe, and 2l of cDNA sample for a
Chapter V: In vitro evaluation of an endothelialized tissue engineered 3D-construct for bone repair
102
total reaction volume of 25l. Assays-On-Demand oligonucleotides were mixed
according to the manufacturers protocol. PCR conditions were 95°C for 10min,
followed by 42 cycles of amplification at 95°C for 15sec and 60°C for 1min using the
GeneAmp 5700 Sequence Detection System (Applied Biosystems, Foster City, CA).
Relative quantification of mRNA targets was performed according to the comparative
CT method with 18S ribosomal RNA for MSC and p0 (large ribosomal protein) for
HUVEC as endogenous controls (Table I).
Table I. Primers and Probes for Real-Time RT-PCR
see chapter II, Table I:
BMP-2
Collagen type I
MMP-13
Osteocalcin
Osteonectin
Osteopontin
Runx2
Assays-On-Demand by Applied Biosystems:
ALP: Hs00758162_m1
Ang1: Hs00181613_m1
Dlx5: Hs00193291_m1
EGFL7: Hs00211952_m1
MMP-2: Hs00234422_m1
MMP-9: Hs00234579_m1
Osx: Hs00541729_m1
p0: Hs99999902_m1
PDGFRB: Hs00182163_m1
Tie1: Hs00178500_m1
Tie2: Hs00176096_m1
VE-cadherin: Hs00174344_m1
VEGFR1: Hs00176573_m1
VEGFR2: Hs00176676_m1
VEGFR3: Hs00176607_m1
vWf: Hs00169795_m1
Self designed probes were modified at the 5’ end with the FAM fluorescent dye (6-carboxyfluorescein)
and at the 3’ end with the TAMRA fluorescent quencher (6-carboxy-N,N,N’,N’-tetramethylrhodamine).
Assay-On-Demand probes had a non-fluorescent quencher at the 3’end.
Chapter V: In vitro evaluation of an endothelialized tissue engineered 3D-construct for bone repair
103
Preparation of cryosections
The grafts were fixed in pure Methanol for one week at 4°C, were transferred
to 5% Sucrose in PBS over night and were cyrosectioned at 6-10µm using Microm
embedding medium (Walldorf Switzerland, cat# 350100), a Cryostat-Microtome HM
560 OMV (Carl Zeiss AG, Zürich, CH) and SuperFrost Plus GOLD microscope slides
(Menzel-Gläser, Braunschweig, De). The slides were left to dry at -20°C for at least 2
days.
Toluidene Blue and van Kossa staining
The dried slides were stained with Toluidene Blue (1% Toluidene Blue in 1%
sodium tetraborate in ddH2O, filtered) for 15min at RT, and then rinsed 2x in dH2O.
Van Kossa stainings were performed by incubating the slides in 5% Silver nitrate for
60min under natural light, rinsing with dH2O, incubating in 5% sodium thiosulfate for
10min, rinsing with dH2O and counterstaining with Nuclear Fast Red followed by
rinsing with dH2O. Coverslips were mounted using aqueous mounting solution
(Hydromount HS-106 by National Diagnostics, Atlanta, GA, USA).
Immunohistochemistry
The dried sections were encircled using a hydrophobic DakoPen (Cat. No. S-
2002, Dako, Glostrup, DK) and were left to rehydrate in PBS-Tween (0.32g/L
NaH2PO4, 1.42g/L Na2HPO4, 9g/L NaCl, 0.1% Tween-20, pH 7.4) for 5min. Non-
specific binding was reduced by incubating the samples in horse serum (diluted 1:20
in PBS, by Vector Labs, USA) for 60min at RT. The primary antibody (polyclonal
mouse anti-human Laminin 2E8 by Developmental Studies Hybridoma Bank;
polyclonal rabbit anti-human vWf: Dako A 0082) was added in the appropriate
dilution (Laminin 1:5, vWf 1:400) and the samples were incubated for 3h at RT. PBS-
Tween was used as control. The samples were washed 3x with PBS-Tween. The
secondary antibody (Laminin: horse anti-mouse IgG antibody by Vectastain cat#
PK6102; vWf: donkey anti-rabbit IgG antibody by RDI cat# RDI-711065152) was
added at 1:200 dilution and the samples were incubated for 30min at RT, before
being washed 3x with PBS-Tween again. Fresh ABC-complex (Vectastain ABC-kit
Elite, cat# PK6102) was added and the samples were incubated for 30min at RT,
before being washed 3x with PBS-Tween. DAB (Vector Laboratories cat# SK-4100)
was added and the samples were incubated in the dark for 4min at RT. The samples
the counterstained in Mayer’s haematoxylin for 3min (Merck 15-938) and were then
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rinsed twice in water for 5min each. Coverslips were mounted using aqueous
mounting solution (Hydromount HS-106 by National Diagnostics, Atlanta, GA, USA).
Immunofluorescence
The dried sections were encircled using a hydrophobic DakoPen and were
left to rehydrate in PBS-Tween (0.32g/L NaH2PO4, 1.42g/L Na2HPO4, 9g/L NaCl,
0.1% Tween-20, pH 7.4) for 5min. Non-specific binding was reduced by incubating
the samples in horse serum (diluted 1:20 in PBS, by Vector Labs, USA) for 60min at
RT. The primary antibody (monoclonal mouse anti-human CD31 antibody by R&D
cat#BBA7; polyclonal rabbit anti-human Osf2 by BioVendor cat#RD181045050) was
added in the appropriate dilution (CD31 1:1000, Osf2 1:400) and the samples were
incubated for 3h at RT. PBS-Tween was used as control. The samples were then
washed 3x with PBS-Tween before being incubated with the fluorescent secondary
antibody (CD31: CY3 sheep anti-mouse IgG antibody at 1:50 dilution by Sigma
cat#C2181, Osf2: Alexa Fluor 488 goat anti-rabbit IgG antibody at 1:400 dilution by
Molecular Probes cat#A11008) for 30min at RT. The samples were washed and
coverslips were mounted using Prolong Gold Antifade reagent (Molecular Probes
cat#P36930) and the samples were stored in the dark until being analyzed.
Cell viability stain
The culture medium was removed from the wells and the scaffolds were
incubated in fresh IMDM containing 1µL/mL EthD1 (Fluka, cat# 46043), diluted from
a stock solution of 1mg/ml EthD1 in 20% DMSO (Fluka cat# 46043) for 10min at
37°C. After washing with IMDM, the scaffolds were incubated in fresh IMDM
containing 1µL/mL calcein AM (Fluka, cat# 11783), diluted from a stock solution of
1mg/ml calcein AM in 100% DMSO for 20min at 37°C. After washing, IMDM
containing 5% FBS was added to the wells and the scaffolds were analyzed by
fluorescence microscopy [43]. In this assay, living cells are distinguished from dead
cells by the presence of ubiquitous intracellular esterase activity, determined by the
enzymatic conversion of the non-fluorescent calcein AM to intensively fluorescent
calcein. Calcein is well retained within living cells, producing an intense uniform
green fluorescent light (ex/em ~495nm / ~515nm). Dead cells were stained using
Ethidium homodimer-1 (EthD1), which only enters the cell with damaged cell
membranes and undergoes a 40-fold enhancement of its fluorescence upon binding
to nucleic acids, thereby producing a bright red fluorescence in dead cells (ex/em
~495nm / 635 nm).
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Microscopical analysis
All histological sections were analyzed using a Zeiss Axioplan 2 Microscope,
a Zeiss Axiocam camera and Zeiss Axiovision software. Zeiss filtersets 10, 15 and 25
were used for fluorescence analysis.
Statistics
Results are shown as mean±SEM of triplicate samples of two independent
experiments (n=6). Statistical analyses were performed using the non-parametric
Mann-Whitney U-test, which compares the medians of two independent distributions.
P<0.05 was considered to be statistically significant.
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Results
Choice of scaffold
Two types of polyurethane scaffolds were compared in order to select the
better one for the 3D-experiments. IsoK-43 was of equal composition as IsoK-40 but
contained an additional ceramic component. After culturing human MSC or HUVEC
in the two different scaffolds for 7 days, cell viability was determined using
EthD1/calcein staining. Microscopic analysis showed, that both scaffolds supported
attachment of MSC and HUVEC. But while IsoK-40 was a clearly hospitable
environment for both cell types after 7 days, the IsoK-43 environment induced cell
death in a large fraction of the attached MSC and HUVEC. The IsoK-40 scaffold was
therefore chosen for the following 3D-experiments.
Green cells are living, red cells are dead:
IsoK-40 seeded with MSC (1.25x) IsoK-43 seeded with MSC (1.25x)
IsoK-40 seeded with MSC (2.5x) IsoK-43 seeded with MSC (2.5x)
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IsoK-40 seeded with HUVEC (1.25x) IsoK-43 seeded with HUVEC (1.25x)
IsoK-40 seeded with HUVEC (2.5x) IsoK-43 seeded with HUVEC (2.5x)
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PRP vs. Fibrin
A common method to seed cells into a scaffold and to retain them inside is
the use of a fibrin sealant. Fibrin is mixed with cells and forms a gel within the
scaffold upon thrombin addition, therefore keeping the cells from being washed out
into the culture medium before their proper attachment to the scaffold. An easy-to-
obtain alternative to fibrin sealant could be PRP, which would have the additional
advantage of containing autologous growth factors and cytokines. We therefore
evaluated the performance of PRP versus fibrin sealant as a carrier for MSC or
HUVEC seeded into IsoK-40 scaffolds by measuring the expression of typical
osteoblastic and endothelial genes using real-time RT-PCR.
MSC generally performed better in PRP than in fibrin, as shown by significantly
elevated gene expression of Col1, MMP-13, BMP-2, OP and OC. BSPII and Runx2
were expressed at similar levels in both PRP and Fibrin. Osterix expression by MSC
could not be detected after 21 days culture time in PRP or fibrin (Figure 1a).
Figure 1a:
Gene expression of MSC
seeded on IsoK-40 scaffolds
using PRP or fibrin sealant:
Typical osteoblastic marker
genes (MMP-13, BMP-2, OP,
OC) showed significantly
(P<0.05) elevated expression
levels when MSC were
cultured in PRP rather than in
fibrin sealant.
HUVEC also performed better in PRP than in fibrin gel, as shown by the significantly
increased expression of the endothelial markers vWf, VE-cadherin, VEGFR2, Tie1,
Tie2, MMP-2 and BMP-2 (Figure 1b). MMP-9 could not be detected after 21 days of
culture.
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Figure 1b:
Gene expression of HUVEC
seeded on IsoK-40 scaffolds
using PRP or fibrin sealant:
All measured endothelial
marker genes were
expressed at significantly
(P<0.05) higher levels when
HUVEC were cultured in PRP
than in fibrin gel.
In summary, we were able to show, that PRP significantly up-regulated the
expression of typical osteoblastic genes in MSC compared to fibrin gel. This would
correlate with our earlier findings, in which PRP was able to enhance osteoblastic
differentiation of MSC in monolayer (see chapter IV). Furthermore, PRP also
significantly enhanced the expression of endothelial cell specific markers in EC when
compared to EC in fibrin gel. It was therefore decided to use the polyurethane
scaffold type IsoK-40 together with PRP as a carrier of cells and biological stimuli.
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Experimental setup for different 3D grafts of MSC and HUVEC
Four 3D-constructs using two different kinds of co-cultures of MSC and
HUVEC seeded on polyurethane scaffolds in combination with PRP were evaluated
(see Scheme below). The indirect co-culture type was a sandwich construct with the
two scaffolds stacked on top of each other and held in place by a PTFE-ring (SW-
construct). The top scaffold was seeded with HUVEC in PRP, the bottom one with
MSC in PRP. The direct contact co-culture type was a mixture of both cells types in
PRP seeded together into one scaffold (Mix-construct). Scaffolds containing MSC or
HUVEC alone were used as controls. Total cell numbers were equivalent in all
constructs.
Scheme of experimental setup of the 3D co-cultures of MSC and HUVEC
Evaluation of gene expression of MSC and HUVEC in 3D constructs
In order to evaluate the different co-culture types, we compared the
expression of typical genes involved in osteoblastic and endothelial cell
differentiation, as well as in bone repair and angiogenesis.
For the scaffolds containing MSC, the following genes were evaluated: Type I
collagen (Col1), type III collagen (Col3), collagenase 3 (MMP-13), osteopontin (OP),
osteocalcin (OC), bone sialoprotein II (BSP), alkaline phosphatase (ALP), distal-less
homeobox 5 (Dlx5), runt-related transcription factor 2 (Runx2), Osterix (Osx), bone
morphogenetic protein 2 (BMP-2) and vascular endothelial growth factor (VEGF).
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Col1 and Col3 expression increased over time (35 days) in all cultures except in
Sandwich-MSC, where Col1 and Col3 were down-regulated. However, in Mix-MSC
both were significantly up-regulated compared to MSC (Figures 2a and 2b).
Figures 2a and 2b: Gene expression of types I and II collagen by MSC at day 35
Similar results were observed for the transcription factors Dlx5 and Osx: Down-
regulation in Sandwich-MSC and significant up-regulation in Mix-MSC at day 35.
Figures 3 and 4: Gene expression of Dlx5 and Osterix by MSC at day 35: There was no Osx detectable
at day 1, therefore Osx expressions is not normalized to day1.
At day 35, MMP-13 was similarly up-regulated in MSC and Mix-MSC compared to
day 1. MMP-13 levels in Sandwich-MSC however were down-regulated to almost
undetectable levels (Figure 5).
Figure 5:
Gene expression of MMP-13 by
MSC at day 35
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Runx2 expression did not change over time in MSC and Sandwich-MSC, but was
significantly up-regulated in Mix-MSC.
Figure 6:
Gene expression of Runx2 by
MSC at day 35
BMP-2 expression decreased over time in both MSC and Sandwich-MSC cultures,
but increased clearly in Mix-MSC.
Figure 7:
Gene expression of BMP-2 by
MSC at day 35
ALP gene expression increased in all cultures over time. However, while MSC and
Sandwich-MSC showed a 3-4x increase at day 35 compared to day 1, Mix-MSC
showed more than 14-fold increase.
Figure 8:
Gene expression of alkaline
phosphatase by MSC at day 35
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Total VEGF expression decreased in all cultures over time except in Sandwich-MSC,
where VEGF increased slightly compared to day 1.
iF gure 9:
Gene expression of total VEGF
by MSC at day 35
Osteopontin, osteocalcin and bone sialoprotein II all were significantly up-regulated in
MSC cultures at day 35 compared to day 1. While OP, OC and BSP levels in
Sandwich-MSC did not change significantly over time, they increased in Mix-MSC,
but surprisingly not as much as in MSC.
Figures 10-12: Gene expression of OP, OC and BSP by MSC at day 35
The expression of osteocrin and Ang1 were also determined, but were at almost
undetectable levels in all types of cultures at all times.
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For the constructs containing HUVEC, the expression levels of the following genes
were evaluated: Endothelin-1 (ET-1), VE-cadherin (CDH5), matrix metalloproteinase
2 (MMP-2), matrix metalloproteinase 9 (MMP-9), von Willebrand factor (vWf), EGF-
like domain 7 (Egfl7), platelet-derived growth factor receptor ß (PDGFRB), BMP-2,
VEGF receptor 1 (Flt1, VEGFR1), VEGF receptor 2 (Flk1, KDR, VEGFR2), VEGF
receptor 3 (Flt4, VEGFR3), Ang1, Tie1 and Tie2 (TEK).
The endothelial markers VE-cadherin and vWf showed both by far the highest
expression levels in Mix-HUVEC, followed by Sandwich-HUVEC and HUVEC. While
all VE-cadherin expression levels at day 35 were lower than at day 1, the expression
levels of vWf by Mix-HUVEC was 3x higher than at day 1.
Figure 13:
Gene expression of vWf by
HUVEC at day 35
Figure 14:
Gene expression of VE-cadherin
by HUVEC at day 35
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Egfl7, MMP-2 and MMP-9, all factors known to be involved in vascular tissue
development, remodeling and repair showed a similar picture. Egfl7 and MMP-2
showed rather low expression levels in HUVEC and Sandwich-HUVEC cultures, but
were highly up-regulated in Mix-HUVEC. MMP-9 was not detectable at day 1 in any
culture, but was highly expressed in Mix-HUVEC at day 35.
Figure 15:
Gene expression of EGF-like
domain 7 by HUVEC at day 35
Figure 16:
Gene expression of MMP-2
(Gelatinase A) by HUVEC at day
35
Figure 17:
Gene expression of MMP-9
(Gelatinase B) by HUVEC at
day 35: There was no MMP-9
detectable at day 1, therefore
MMP-9 expression is not
normalized to day 1.
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The expression of endothelial receptors VEGFR1, -2, -3, Tie1, -2, and PDGFRB were
clearly highest in the Mix-HUVEC and lowest in the HUVEC cultures. Interestingly,
the expression levels at day 35 compared to day 1 were only increased for VEGFR3
(> 4 times) and for PDGFRB (> 2500 times), while only a slight increase was
observed for VEGFR2. The expression levels of all other receptors decreased with
culture time.
Figures 18 and 19: Gene expression of VEGFR1 (Flt1) and -2 (Flk1, KDR) by HUVEC at day 35
Figures 20 and 21: Gene expression of VEGFR3
(Flt4) and PDGFRB by HUVEC at day 35
Figures 22 and 23: Gene expression of Tie1 and Tie2 (TEK) by HUVEC at day 35
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BMP-2 and ET-1, both factors that are known to affect bone cells, were also most
prominently expressed in Mix-HUVEC, followed by Sandwich-HUVEC and HUVEC
cultures. ET-1 levels were generally lower at day 35 than at day 1, but BMP-2
significantly increased over time in Mix-HUVEC.
Figure 24:
Gene expression of bone
morphogenetic protein 2 by
HUVEC at day 35
Figure 25:
Gene expression of endothelin-1
by HUVEC at day 35
Ang1 expression significantly increased over culture time to comparable levels in
HUVEC and Mix-HUVEC but remained almost undetectable in Sandwich-MSC.
Figure 26:
Gene expression of Ang1 by
HUVEC at day 35
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Histological analysis of 3D-constructs
The gene expression pattern of constructs containing a mix of MSC and
HUVEC (Mix-constructs) clearly showed an up-regulation of genes involved in
angiogenesis and bone formation. To further explore this promising data, we
performed histological analyses of constructs.
Van Kossa staining of Mix-constructs at day 21 showed mineral deposition in small
distinct areas of the graft (Figure 27 right). There was no mineral deposition in MSC
(Figure 27 left) or in SW-constructs (not shown).
Figure 27: Van Kossa stain at day 21: Constructs containing MSC alone (left) showed no mineral
deposition while in the constructs containing a mix of MSC and HUVEC (right), there was mineral
deposition in distinct areas (arrows).
Figure 28: Van Kossa stain of Mix-constructs at day 21: The left picture shows elongated cells lining the
outside of the construct while in the inside, calcium is deposited into the matrix.
See Fig. 28 left
See Fig. 28 right
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Evaluation of cell morphology at day 21 using Toluidene Blue staining revealed
interesting changes in cell shape. We observed the development of elongated cells in
Mix-constructs (Figure 29). The fact that these elongated cells are always appearing
in groups suggests that these cells might be starting to form a network. Nothing
similar could be found in the other constructs (Figure 30).
Figure 29: Toluidene Blue stain of Mix-constructs at day 21 revealed assemblies of elongated cells
suggesting a possible start of network formation. Bar represents 50µm.
Figure 30: Toluidene Blue stain of constructs containing MSC (left) or HUVEC (right) at day 21 showed
no remarkable morphological characteristics. Bar represents 50µm.
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By using higher magnification in Mix-constructs, we observed cells forming an
intracellular lumen (Figure 31 left and center) and also intercellular lumen in between
two cells (Figure 31 right).
Figure 31: Toluidene Blue staining of Mix-constructs at day 21: Intracellular lumen formation (left,
center) and extracellular lumen formation between two cells (right). Bar represents 20µm.
At day 35, Toluidene Blue staining revealed the formation of tube-like structures in
Mix-constructs. Almost all cells were attached to these structures, with only very little
cells left in-between these tubules (Figure 32).
Figure 32: Toluidene Blue staining (bar represents 50µm) at day 35: Tube-like structures in Mix-
constructs (left). Grafts containing only MSC did not show such structures (middle). Grafts containing
only HUVEC showed similar, yet much less and only very short tubular-like structures (right).
We further explored these tubular structures by immunohistochemical analysis at day
35. Using an antibody against laminin, we were able to reveal possible tube-like
structures in the Mix-constructs, consisting of a wall and a more or less continuous
lumen (Figure 33). Those structures were exclusively found in Mix-constructs.
Intracellular Intracellular Intercellular
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Figure 33: Immunostaining using an antibody against laminin on Mix-constructs at day 35: tubular
structures containing extensive lumen (arrows). Bar represents 20uM.
Immunostaining of these tubular structures with an antibody to von Willebrand factor
revealed that they were highly multicellular (Figure 34a). Interestingly, not only
endothelial cells (smaller darker nuclei) were visible, but also cells featuring a larger
unstained nucleus were participating in these tubular structures. This suggests that
also MSC might contribute to these structures (Figure 34b).
Figure 34a: vWf immunostaining of Mix-construct at day 35: Large multicellular tube-like structures
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Figure 34b: vWf immunostaining of Mix-constructs at day 35: Large unstained nuclei (arrows) seem to
contribute to the tubular structures. They possibly represent MSC. Bar represents 20µm.
To confirm, that also MSC contribute to these tubular structures, we performed an
immunofluorescence analysis using an antibody against the osteoblastic transcription
factor Osf2 (gene product of Runx2). The presence of osteoblastic cells on the
tubular structures was confirmed (Figure 35), even though our antibody produced
considerable unspecific background-staining. Examples of specific bindings are
marked (arrows).
Figure 35: Osf2 immunostaining of Mix-construct at day 35: Large areas of the tube-like structures
show the presence of Osf2-positive cells, most probably differentiating MSC.
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Immunofluorescent staining using an antibody to the EC surface marker CD31
confirmed the formation of tube-like structures by EC (Figure 36).
Figure 36: Immunofluorenscence using an antibody to CD31 in Mix-constructs at day 35: Tubular
structures as found only in Mix-constructs. Bar represents 20µm.
Endothelial cells were also found covering various surfaces, especially in Mix-
constructs, further confirming their increased urge to fulfill their natural fate by
building natural barriers. Figure 37a shows the outside of a graft covered by CD31-
positive cells. Figure 37b shows CD31-positive cells forming circular structures within
the PRP gel.
Figures 37a and b: Immunofluorescence of Mix-constructs at day 35: Endothelial cells (CD31+)
covering the outside of a graft (left), and forming circular structures in PRP-gel (right).
In conclusion, we have shown significant up-regulation of osteoblastic
markers in Mix-constructs. Also, angiogenic and endothelial markers expressed by
HUVEC were significantly up-regulated in this construct type. This was in contrast to
the much lower gene expression levels in non direct-contact co-cultures (Sandwich)
and constructs seeded with MSC or HUVEC alone.
Furthermore, histological analysis revealed the formation of inter- and intracellular
lumen as well as the presence of tubular and circular structures in Mix-constructs
only.
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Discussion
The aim of this study was to define an optimal scaffold-cell construct in vitro
to serve as a potential alloplastic bone graft in vivo that could overcome the problem
of insufficient vascularization in large bone defects. In addition, since during bone
tissue repair in vivo fibrin clots are an important source of growth factors and
cytokines, we evaluated the use of platelet-rich plasma (PRP) as a supplier of
osteoinductive and angiogenic factors within the construct.
In previous studies (diplomawork), we have evaluated different scaffolds to be used
in bone and cartilage tissue engineering using osteoblasts, chondrocytes and bone
marrow aspirates. Based on these early results, we decided to use a biodegradable
polyurethane scaffold for our endothelialized construct [44, 45]. Many studies have
used calcium-phosphates (CaP) like ß-tricalcium-phosphate (ßTCP) or
hydroxyapatite (HA) because of their “natural” composition as well as their superior
mechanical strength. However, calcium phosphate based materials have also
significant drawbacks, like the lack of macro-pores, resulting in impaired vessel
ingrowth as well as their layered biodegradation (from the outside to the inside). In
addition, due to the stiff properties of CaP, there is considerable friction at the bone-
implant interface resulting in wear-debris, limited vessel ingrowth and implant
integration. Biodegradable polyurethanes on the other side are very macro-porous
and elastic, and can therefore be fitted very tightly into the site of injury, providing a
more flexible tissue-implant interface that facilitates vessel ingrowth and implant
integration. It has previously been shown that PU scaffolds can be seeded with
chondrocytes up to 42 days without any apparent toxicity [46, 47]. In addition, similar
polyurethane scaffolds were used in an iliac bone defect in a pilot experiment in
sheep [48]. Therefore, we considered polyurethane as a potential scaffold for bone
substitutes. Two different kinds of isosorbide polyurethane scaffolds were compared
in this study. Both scaffolds were identical except that one contained a ceramic nano-
phase. However, this ceramic component seemed to be harmful to our cells, we
therefore decided to continue with the polyurethane scaffold that did not contain the
mineral phase. The reason for this toxic effect is not clear. A possible explanation
could be that the ceramic phase in the PU scaffold somehow hinders the removal of
ethylene oxide after sterilization so that detoxification was not carried our long
enough. Further experiments will be necessary to resolve this issue.
When seeding cells within a 3D structure with pore sizes between 200 to 500
microns, it is almost impossible to retain the cells within the scaffold structure. In
addition, cell aggregates will occur, making cell distribution far from being
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homogeneous [46]. A common way to avoid these cell-seeding problems is the use
of fibrin gel [42]. Although fibrin is commonly used in surgery, its animal origin
(bovine) raises some concerns about its safety. Therefore, autologous PRP would be
a much better solution. As reported in chapter IV of this thesis, we were able to show
that PRP had a strong osteogenic effect on MSC in monolayer culture. PRP contains
a large amount of different growth factors and cytokines, including TGF-ß, PDGF,
FGF, IGF and EGF [49, 50].
We therefore have evaluated the effect of PRP versus fibrin gel as a carrier for MSC,
HUVEC or a combination of both. Our findings showed that when MSC were cultured
in PRP gels, a much higher expression of the typical osteoblastic genes was
observed compared to MSC cultured in fibrin. This was most prominently seen in the
expression of type I collagen, osteocalcin, osteopontin, MMP-13 and BMP-2. These
results are in agreement with our earlier observations on the effect of PRP on MSC in
monolayer (see chapter IV). However, the gene up-regulation observed in the 3D
environment was generally higher than that measured in monolayer. The by far most
up-regulated gene was MMP-13, an endopetidase known to be involved in matrix
turnover by its ability to cleave collagen triple helices, aggrecan core protein,
fibronectin and other components of the extracellular matrix. MMP-13 and other
MMPs (especially MMP-2 and -9) have been shown to be tightly connected to the
process of angiogenesis and blood vessels ingrowth [31, 32]. Interestingly, also the
expression of early and late bone matrix proteins such as Col1, OP and OC was up-
regulated by PRP. This suggests that PRP also enhances the differentiation of
precursor cells into mature osteoblasts.
We also measured the performance of PRP versus fibrin gel as a carrier for HUVEC
by comparing the gene expression levels. The same picture as with MSC was
observed: PRP greatly enhanced the expression of endothelial cell markers such as
vWf, VE-cadherin and the endothelial receptors VEGFR2, Tie1 and Tie2. BMP-2
expression by HUVEC in PRP was also significantly up-regulated. We also had an
up-regulation of MMP-2, which has been shown to be involved in angiogenesis.
MMP-2 is the most abundant MMP produced by endothelial cells. MMP-2 is
constitutively secreted as a zymogen and is believed to play a role during the initial
steps of angiogenesis [51, 52]. Interestingly, MMP-9 (or 92kDa gelatinase), another
MMP thought to be involved in angiogenesis was not detected after 21 days of
culture, but was present after 35 days. From these experiments it was obvious that
PRP was far superior to fibrin in inducing MSC differentiation into an osteogenic
phenotype, as well as in stimulating typical EC markers on HUVEC.
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We then focused on 3D co-culture experiments of MSC and HUVEC using PRP as a
carrier. Two types of co-cultures were established. The first one was an indirect-
contact co-culture, where HUVEC and MSC were seeded in two polyurethane
scaffolds using PRP, and these two scaffolds were placed on top of each other
(Sandwich). The second one was a direct contact co-culture, where MSC and
HUVEC were seeded within the same polyurethane scaffold using PRP (Mix).
Analysis of MSC gene transcription revealed, that Sandwich co-cultures resulted in a
down-regulation of many osteoblastic genes, including Col1, Col3, OP, OC, BSP,
Dlx5, Osx and MMP13. These results were in close agreement with our earlier
indirect contact co-culture results, in which EC were shown to inhibit MSC
differentiation (see chapter II). However, in Mix co-cultures (direct contact) a
significant increase in a variety of osteoblastic markers, including Col1, Col3, Runx2,
Dlx5, Osx, BMP-2, ALP and MMP13 was observed.
Type III collagen, which is generally much less abundant than type I collagen, is
typically not found in bone, but is highly expressed around blood vessels. Thus, the
up-regulation of Col3 in Mix co-cultures might suggest that the formation of blood
vessels might be induced. Up-regulation of the early transcription factors Runx2 and
Dlx5 as well as the most specific known osteoblastic transcription factor Osx in Mix-
cultures clearly indicates that MSC are differentiating towards the expression of an
osteoblastic phenotype. An interesting observation is that in Sandwich co-cultures,
Runx2 expression is not altered compared to MSC alone, but Osx (and also Dlx5) is
significantly down-regulated. This observation suggests again that a positive effect
on MSC differentiation is observed only when MSC and EC are in direct contact. The
bone matrix proteins OC, OP and BSP were also up-regulated in Mix co-culture at
day 35 compared to day 1.
Analysis of the expression of the different EC genes revealed that most of these
markers were significantly up-regulated by both co-culture types (Sandwich and Mix).
However, in Mix co-cultures, up-regulation of EC markers was much higher than in
Sandwich co-cultures. Interestingly, MMP-2 and -9 were highly up-regulated in Mix-
cultures. Egfl7, VEGFR2, Tie1 and -2 as well as VE-cadherin are all EC markers
appearing rather early in EC maturation events, while PDGFRB and vWf are later
markers of vascular maturation [23] [22, 53]. Therefore, it is normal that VEGFR2,
Tie1, Tie2 and VE-cadherin were expressed in all cultures containing EC. However,
PDGFRB and vWf, were only prominently expressed in Mix-cultures, suggesting
again that EC were able to undergo maturation only in direct contact co-cultures.
Another important EC marker, endothelin-1, was up-regulated in both co-cultures
(Mix higher that Sandwich) compared to EC alone. ET-1 has been shown to be a
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major player in the signaling between EC and osteoblasts during bone development,
remodeling and repair and is known to stimulate osteoblasts proliferation and
differentiation [54, 55]. Another interesting observation was that ET-1 has been
shown to down-regulate VEGF expression in long-term cultures of osteoblasts [55], a
finding that we have also observed in the present study. In Sandwich-cultures, VEGF
expression was high while ET-1 expression was low. In contrast, in Mix-cultures,
VEGF expression was low and ET-1 was high. So the inhibitory effect of ET-1 on
VEGF expression occurs only when MSC and EC are in direct contact, which might
suggest a tight coupling between the angiogenic and bone formation processes.
BMP-2, which has been shown to induce the expression of the osteogenic master
transcription factors Runx2, Dlx5 and Osx in MSC [56, 57] was significantly up-
regulated in Mix co-cultures. In addition, all those osteogenic master genes were, as
expected, also significantly up-regulated in Mix-cultures.
These findings at the gene expression level were then confirmed by histological
analyses. We were able to show, that only in Mix-cultures calcium deposition occurs.
Furthermore we observed multicellular tube-like structures in Mix-cultures formed by
HUVEC and possibly stabilized by differentiating MSC. We also detected cells
forming intra- and intercellular lumen. Unfortunately, we were not able to study the
formation of these structures over time, so we cannot conclude by which
mechanisms these structures were formed. However, it seems clear that our
constructs containing MSC and HUVEC in PRP promoted EC to form separating cell
layers, which eventually might result in functional blood vessels.
In conclusion, constructs consisting of a mixture of MSC and EC seeded on a
polyurethane scaffold within a PRP environment might be a very promising
alternative to autologous bone grafting.
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Chapter VI
Isolation of CD34+ cells from blood aspirates and
differentiation into endothelial cells
Meury TR, Alini M
Our aim was to define a 3D construct, which consisted of as many autologous
components as possible. This chapter summarizes our attempts to isolate CD34+
cells from blood samples and to differentiate them into mature endothelial cells.
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One of our aims was to develop a full construct made of autologous material.
We succeeded by using MSC and PRP in our constructs, which can be easily
obtained from the patient’s bone marrow and blood respectively.
The initial plan was therefore also to obtain endothelial cells from an autologous
source. Endothelial progenitor cells (EPC) and hematopoietic stem cells (HSC) share
some surface molecules like VEGFR2, Tie2 and CD34. This led to the assumption,
that these progenitors may have a common precursor cell present within the
peripheral blood system [1, 2]. This hypothesis that blood might contain EPC was
also supported by studies showing that the luminal side of artificial vascular grafts in
vivo becomes eventually covered by EC [3, 4]. Asahara was the first to actually show
that EPC can be isolated from peripheral blood and can be differentiated into
endothelial-like cells [5]. A cell surface marker generally used for EPC isolation is
CD34. It is not only expressed EPC but also on HSC and is lost during hematopoietic
differentiation [6, 7], but not during EC differentiation and maturation [8-10]. Based on
these studies, we decided to isolate CD34+ cells from human blood samples and
differentiate them into endothelial cells, in order to obtain also EC from an autologous
source.
From CD4-negative buffy-coat (kindly obtained from the local Asthma Research
Institute SIAF in Davos), using the MiniMAC Magnetic Microbead System (by Miltenyi
Biotec, Germany), we isolated CD34+(/CD4-) cells (MACS Direct CD34 Progenitor
Isolation Kit, cat# 467-02) using the following procedure:
Buffy-coat was centrifuged at 1’500g for 10min at RT and the resulting pellet was
resuspended in MiniMAC Buffer (2mM EDTA, 0.5% BSA in PBS, degassed) at a
concentration of 108 cells/100µL. 100µL of FcR Blocking Reagent was added. The
cells were then labeled by addition of 100µL of CD34 Microbeads per 108 total cells
followed by incubation for 30min at 8°C under gentle agitation. After carefully
washing with MiniMAC Buffer, the labeled cells were resuspended in 1mL of
MiniMAC Buffer and were added to a pre-wetted separation column positioned in a
magnetic stand. The separation column was washed 3x with MiniMAC Buffer, was
removed from the stand and the CD34+ cells were eluted from the column into a
fresh tube with MiniMAC Buffer. CD34+ cells were then centrifuged, resuspended in
medium and seeded into flasks.
Different coatings of the culture flasks (no coating, gelatin, fibronectin) were tested.
We also evaluated different initial seeding concentrations and most importantly,
compared different media and supplements, including F-12K and IMDM in
combination with serum, as well as several serum-free media like StemSpan (Stem
Cell Technologies, cat# 09650) and StemPro-34 (Gibco, cat# 10639-011). Finally, we
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settled on the serum-free StemPro-34 as EPC growth medium. In addition, various
types of rather expensive commercial supplements and different combinations of
cytokines and recombinant growth factors (including IL-1, IL-3, IL-6 and SCF, Flt-3,
TPO and GM-CSF) for the expansion of CD34+ cells were evaluated. In the end, we
were able to isolate CD34+ cells from buffy-coat and culture them in StemPro-34
medium, supplemented with IL-3, IL-6 and SCF (all at 50ng/mL). The concentrations
of IL-3, IL-6 and SCF were based on a personal communication with Dr. Nicolai
Ferrari [11].
The plan was then to check the phenotype of CD34+ cells after isolation by FACS
analysis, to expand them for one or two weeks and then to recheck their phenotype
by measuring the following surface markers: CD34, VEGFR2, CD133, CD45 and
CD14. Depending on the results, a reselection of CD34+ and further expansion
would have been evaluated. Then we would have differentiated the CD34+ cells into
EC by stimulating them with a combination of ECGF and VEGF, both at 50-
100µg/mL (again based on personal communication with Dr. Nicolai Ferrari) in
different culture mediums like RPMI, F12K or M199.
While planning all these experiments we realized, that this sub-project was growing
into a project itself. Especially the cell-characterization during differentiation of
CD34+ cells into endothelial cells would have taken too much time and would have
shifted our experimental aims too far away from the initial focus of this PhD thesis.
We therefore decided to continue our experiments using primary human
umbilical vein endothelial cells (HUVEC) purchased from Cascade Biologics. We are
of course aware that HUVEC are different from the microvascular EC found in the
bone vasculature. However, we chose HUVEC since they are well characterized and
easy to handle, compared to microvascular EC.
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One of the main problems arising when implanting a graft into a large bone
gap is its insufficient vascularization in the central region. This results in impaired
bone healing and often leads to necrosis in the graft. Vascularization and bone
formation have been shown to be very closely connected [1-6]. In order to better
understand the relationship between blood vessels and bone formation, we have
studied the interactions between mesenchymal stem cells (MSC) and endothelial
cells (EC). Since the blood vessel network undergoes dramatic remodeling during
wound healing, a process that is connected with different endothelial cell
maturational stages (reflected i.e. by different cell surface markers), we have also
investigated the effect of growth factor-stimulated EC on MSC differentiation into
bone forming cells. In addition, since during bone healing, one of the first events is
the formation of a blood clot at the site of injury, we have evaluated the potential of
platelet-rich plasma (PRP) as an osteoinductive substance by assessing its action on
MSC differentiation. Finally, our last step was to combine all components into one
autologous construct and to in vitro evaluate its potential to serve as a possible bone
graft that could overcome the in vivo problem of limited vascularization generally
occurring in large bone defects.
Aim 1:
Study the influence of EC on MSC differentiation into an osteoblastic phenotype
The first experiments of this PhD investigated the effect of EC on MSC
differentiation towards an osteoblastic phenotype in monolayer cultures. At that time,
in vitro communication between EC and osteoblastic cells had been reported in few
publications with rather divergent outcomes [7-9]. The only generally accepted fact
was that there must be some kind of communication between these two cells types,
since the appearance of vessels precedes bone formation [5, 6, 10]. We showed that
EC do not stimulate MSC differentiation into osteoblasts in non-direct contact co-
cultures. On the contrary, EC significantly inhibited osteoblastic differentiation of
MSC. We also demonstrated that this inhibitory effect by EC was increased following
stimulation of EC with VEGF. From a mechanistic point of view, this inhibitory effect
was due to the down-regulation of Osx. These findings observed in 2D cultures were
confirmed in our 3D experiments. However, when MSC and EC were cultured
together in direct contact co-cultures, MSC differentiation was induced, and Osx
expression was up-regulated. These observations suggest that EC have a dual
potential to influence osteoblastic differentiation that largely depends on the type of
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communication between these two cell types as well as the maturational stage of EC.
It seems that soluble factors released by EC inhibit, while direct contact with EC
induces osteoblastic differentiation of MSC. One may therefore speculate that,
depending on the developmental stage of the vascular system at a bone repair site,
EC may induce either recruitment of osteoblastic precursor cells, or differentiation of
these precursor cells into osteoblasts.
Aim 2:
Test the suitability of platelet-rich plasma (PRP) as a source of autologous biological
factors in bone tissue engineering
The second part of the PhD focused on factors that could influence bone
formation and angiogenesis in a potential bone graft. Although many studies at that
time had focused on recombinant growth factors to improve bone healing (i.e. BMP
or PDGF) [11-18], we were interested in a more autologous approach. Platelet-rich
plasma (PRP) was a very new “material” that had been used by few people as an
injectable substance or in combination with a scaffold, mainly in maxillofacial and
dental surgery [19-21]. We wanted to use PRP in combination with MSC and have
therefore explored the ability of PRP to induce osteoblastic differentiation in MSC.
Since no standard protocol for the production of PRP was available (everyone used a
different method), we first defined our own PRP preparation and activation method,
which resulted in the filing of a patent for PRP activation by sonication (pending). We
then tested the effect of PRP on MSC differentiation in monolayer as well as in 3D,
and showed that PRP had the ability to greatly enhance osteoblastic differentiation of
MSC. Furthermore, we showed that PRP also greatly enhanced the expression of
many typical endothelial markers on EC in 3D-cultures.
In summary, we were able to isolate and activate PRP in an easy and quick way. We
have also shown that PRP has the potential to induce osteogenic differentiation of
MSC. Furthermore, because of the ability of PRP to form a gel upon activation, PRP
has the capability to serve as an ideal carrier material for MSC and EC in a 3D
construct.
Aim 3:
Define and evaluate an autologous 3D-construct in vitro with the potential to improve
graft vascularization in vivo
The final part of this PhD work combined the results obtained in the other
parts. Our constructs were designed using isosorbide single-phase polyurethane
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scaffolds, seeded with combinations of cells in PRP. We showed that MSC and EC
suspended in PRP could be cultured for at least 35 days in shared culture medium,
without further addition of any growth factors or cytokines (they are probably present
in the PRP). We then showed that direct contact co-cultures of EC and MSC in a 3D
environment resulted in a significant up-regulation of osteoblastic markers in MSC,
and endothelial markers in EC. Furthermore, histological analyses revealed tube-like
structures and cells forming intra- and intercellular lumen in Mix-constructs.
Interestingly, it seemed that MSC and EC both contributed to those tubular
structures. We are aware, that this does not imply that vessels are about to form in
this in vitro setting, but it shows that direct contact of MSC and HUVEC in a 3D
environment containing PRP might have the potential to form a highly vascularized
graft in vivo.
Future Perspectives
Overall, we believe to have contributed to a better understanding of the
cellular interactions between MSC and EC. We have successfully used this
knowledge to develop an endothelialized construct, ready to be used in in vivo
experiments. Of course every answer raises another question.
• How would VEGF influence EC in direct contact co-cultures with MSC, or in
3D ?
• Which changes in the EC phenotype, induced by VEGF, are responsible for
the effects described in chapter II ?
• The effect of angiopoietins on HUVEC-modulated MSC differentiation should
be further explored, probably by using higher Ang1 concentrations and by
including Ang2 (in combination with VEGF) into the studies. It is known that
Ang2 action is largely dependent on the presence or absence of VEGF (see
chapter I).
• Some of our 3D experiments (chapter V) will need to be repeated to confirm
our results. The histological analyses should be expanded by using other
markers, such as NG2, a pericyte cell surface marker. One might speculate
that the MSC contributing to the tube-like structures differentiate into
pericytes, fibroblasts or smooth muscle cells. This speculation should be
explored.
• In order to be able to produce a completely autologous construct, we should
reactivate the studies about generating endothelial cells from blood samples
according to our protocols suggested in chapter VI.
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• Finally it will be interesting to see how our construct performs in vivo,
compared to empty scaffolds, or constructs missing the PRP (replace by fibrin
gel) or the endothelial cells.
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